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Abstract 
Use of small organic molecules in asymmetric organic transformations has been 
popularly increasing every year since the turn of this century. The disadvantages 
associated with the use of transition metal-based catalysts in organic synthesis can be 
overcome by using small organic molecules; organocatalysts. In comparison to other 
firmly established asymmetric catalysis fields such as enzymatic catalysis and 
organometallic catalysis, organocatalysis offers some fundamental advantages: In 
general, organocatalysts can be used in a wider range of solvents and for a broader 
scope of substrate in comparison to enzymes. In addition, they are naturally less toxic 
and less sensitive towards oxidation and moisture than most organometallic based 
reagents.  
This work describes the development of two peptide based triazole organocatalysts for 
the asymmetric Michael addition reactions. These two catalysts were prepared from 
simple amino acids L-proline and L-asparagine using simple and scalable click and acid-
amine coupling reactions. Synthesised catalysts were evaluated for their catalytic 
activity in asymmetric Michael addition reaction of cyclohexanone to various nitro 
olefins which produced Michael adducts with high (up to 99%) enantio- and diastereo- 
selectivities. In addition, transition state energies of four possible enamine-nitrostyrene 
transition states i.e anti-re, anti-syn, syn-re and syn-si were computationally calculated 
and these computational or modelling studies revealed the possible reaction 
mechanism which proceed via formation of anti enamine-re nitrostyrene transition 
state.  
Besides developing proline-triazole peptides for organocatalysis, it was of parallel 
interest to prepare and investigate hybrid triazole derivatives for anti-cancer 
properties. Cancer chemotherapy- in short can be described as treatment of cancer with 
drugs or chemical substances which kills cancer cells. Currently, 50% of patients are 
undergoing chemotherapy, to remove micro metastasis. However, chemotherapy is able 
to cure about 10-15% of all cancers. Development of drug resistance in cancer cells to 
the existing anticancer drugs and undesirable effects of the drugs used in cancer 
treatment stimulates the need of developing new anticancer agents which selectively 
kills the cancer cells.  
xx 
 
Many triazole containing compounds exhibit extensive range of pharmacological 
activities including potent anticancer properties, for instance, cefatrizine, tazobactam 
and carboxyamidotriazole. Whereas, 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-
one derivatives have diverse therapeutic applications in medicinal chemistry. 
Diazepinomicin is an unusual farnesylated-dibenzodiazepinone secondary metabolite 
isolated from micromonospora also contains the dibenzodiazepinone skeleton, 
possesses anti-tumor, anti-bacterial, and anti-inflammatory activity, has also 
demonstrated in vivo activity in mouse models against breast, prostate, glioma tumours 
and induced cytotoxicity in human hepatocellular carcinoma cell lines. It was 
anticipated that, the combination of two pharmacophores dibenzodiazepinone and 
triazole may produce chemical entities with good anti-cancer and/or other biological 
properties. 
Work in Chapter IV describes the preparation of a series of dibenzodiazepinone-triazole 
hybrid derivatives and their cytotoxic activity evaluation in five human cancer cell lines. 
Among the tested dizepinone derivatives, compounds without substitution on benzene 
ring (attached to triazole) exhibited potent tumour growth inhibition in all tested 
cancer cell lines. The simple synthetic preparation and their biological properties make 
these dibenzodiazepinone-triazole scaffolds promising new entities for the 
development of cancer therapeutics. 
 
 
 
 Chapter- II ter - I 
Introduction and Review of  Peptide Catalysis 
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1.1 Introduction 
The importance of enantiomerically pure substances in the pharmaceutical industry is 
enormous; in pharmacological perspectives ‘purity’ equates to ‘value’ of the product. 
From this perspective, environmentally benign, selective high yielding methods are 
integral to the development and synthesis of new therapeutics and new chemical 
entities. This, coupled with the significance of chirality in nature and, more importantly, 
the human body, makes the efficient, green, generation of enantiomerically enriched 
products a key goal in organic synthesis. Enzyme-catalysis and transition metal-
catalysis has emerged as powerful branches of asymmetric synthesis to generate chiral 
organic scaffolds. Most commonly, transition metal complexes are used as asymmetric 
catalysts in industry because of their high reactivity and selectivity. However, the metals 
used are often expensive, difficult to recover from the reaction products, and toxic. 
These issues which are most problematic in pharmaceuticals can be resolved by 
employing organocatalysis. Besides the frontiers of pure transition metal catalysis and 
enzymatic transformations, a third approach for the catalytic synthesis of 
enantiomerically pure organic compounds has emerged -organocatalysis. The use of 
organic compounds as asymmetric catalysts complements the traditional use of 
organometallic and biological approaches to asymmetric catalysis. Organocatalysts are 
metal-free and thus they are likely to be non-toxic to biological systems, and they are 
readily accessible. Unlike metal catalysts organocatalysts are stable and are not air-
sensitive. Another advantage is ‘operational simplicity’; allowing the performance of 
reactions (unlike the inert conditions required for many transition metal catalyzed 
reactions) in air, in wet solvents and directly in water. Organocatalysts enable the 
construction of important chiral scaffolds in an efficient and stereoselective manner by 
coordinating to the substrate which renders it more reactive. Based on mechanistic 
classifications, organocatalysis can generally be categorised as either Lewis base, Lewis 
acid, Brønsted base or Brønsted acid mediated. In 1928 Wolfgang Langenbeck1 
pioneered the term ‘organic catalysts’, this type of approach was also sometimes 
referred to as metal-free catalysis. In 1998 David MacMillan15 coined the word 
‘organocatalysis’ and this term has been generally adopted and used by all. 
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Scheme 1.1 The Hajos-Parrish-Eder-Sauer-Wiechert reaction 
 
The first breakthrough in organocatalyzed enantioselective reactions was observed in 
late 1970’s with the discovery of the Hajos-Parrish-Eder-Sauer-Wiechert2 reaction, 
namely the intramolecular-aldol-cyclodehydration of ketone 2 to Wieland-Miescher 
ketone 3 catalysed by the amino acid (S)-proline1(Scheme 1.1). Since then, this 
transformation has been widely used as a tool for the construction of steroidal 
skeletons3. Surprisingly, however for the next thirty years, the proline1 catalytic efficacy 
in asymmetric aldol and other transformations was not explored further and not 
utilized until List et al. reported their studies4a in 2000. 
 
 
 
Scheme 1.2 (S)-proline catalysed asymmetric intermolecular aldol reaction, List et al. 
 
In this work, the proline catalysed addition of acetone to various aldehydes to afford 
corresponding aldol adducts with excellent chemo- and enantioselectivity. For example 
the addition of acetone to iso-butyraldehyde gave product 4 in 97% yield and 96% 
enantiomeric purity (Scheme 1.2). Almost simultaneously MacMillan reported4b 
iminium-type catalysis of an asymmetric Diels-Alder reaction between cyclopentadiene 
5 and cinnamaldehyde 6, with a chiral imidazolidinone 7 (Scheme 1.3). These two 
publications initiated the launch of organocatalysis as a new important research field in 
asymmetric synthesis. Both works provided well defined mechanistic insights, which 
was undoubtedly crucial for the ensuing widespread organocatalytic applications. 
Today organocatalysis is recognized as a matured field with many synthetic chemistry 
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groups actively working in this field.  The literature in organocatalysis is exponentially 
increasing yearly.5 
 
Scheme 1.3 Imidazolidinone (iminium) catalysed Diels-Alder reaction 
1.2 Peptide catalysis 
Peptide catalysis is the acceleration of reactions mediated by peptides. The basic units 
of enzymes, single amino acids, have provided the route to several attractive methods in 
asymmetric synthesis, as both auxiliary scaffolds and catalysts. Towards the middle of 
the catalyst size continuum, peptides composed of tens of amino acids have found 
increased applications as effective catalysts for various enantioselective methods. The 
use of peptides as asymmetric catalysts, has recently started to flourish.6 Below 
presented sections describe the importance and use of peptide catalysis. 
1.2.1 Significance of peptide catalysis 
Peptides provide many sites to alter functionality; this is attractive because introduced 
modifications provide fine tuning of the catalytic properties. This is an advantage over 
using simple or rigid amino acids. Enzymes are very reaction-sensitive and substrate 
specific and respond to minute changes in the substrate. However, peptides unlike 
enzymes are much more stable and not as substrate specific. The β-turn inducing7-9 
secondary structures of peptides provide good reaction selectivities.  
 
 
Scheme 1.4 Asymmetric epoxidation of chalcone to enantiomerically enriched epoxide 
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These advantages attracted a lot of researchers to utilize peptides successfully in many 
organic transformations. The earlier works of Inoue and Oku8 demonstrated that poly 
(amino acids) is effective catalysts for the conjugate addition of thiols to enones. The 
work of Julia and Colonna9 illustrated that, catalytically active peptides 8a-c can be 
employed in the epoxidation of chalcone 9 to afford levorotatory epoxide 10 in 28-97 % 
optical purity (Scheme 1.4). Despite this intriguing work, the use of peptides as 
asymmetric catalysts remained dormant until the turn of the 21st Century.  In 1998, 
Miller and co-workers introduced10 methylimidazole containing peptide 11 as an 
asymmetric catalyst for the kinetic resolution of alcohols 12 (Scheme 1.5) providing 
excellent enantio-selectivities. This contribution from Miller’s group then established 
chiral catalysis using peptides as an attractive area of asymmetric catalysis. 
 
Scheme 1.5 Miller's kinetic resolution of alcohol using peptide catalyst 11 
 
1.2.2 Applications of peptides in organic synthesis 
Numerous peptides ranging from small to medium size have been used as asymmetric 
catalysts by several groups’ for variety of chemical transformations in the last three 
decades. In recent years peptides have become increasingly popular as catalysts for a 
range of organic transformations, often yielding required products under mild reaction 
conditions in high stereo selectivities. 
1.2.2.1 Hydrocyanation reactions 
Asymmetric hydrocyanation of carbonyls or imines gives useful chiral scaffolds like α-
aminoacids, 1,2-aminols, 1,2-diamines and α-hydroxyacids. The asymmetric addition of 
HCN to benzaldehyde 14 (Scheme 1.6) catalysed by 2,5-diketopiperazine cyclo-Phe-His 
13a (Figure 1.1) was reported by Oku et al8 in late 1979. Solvent polarity, temperature 
of the reaction considerably affected the enantioselectivity of the product. Surprisingly, 
product ee’s  were different when ‘wet solvent purified’ and ‘dry solvent purified’ 
peptides were used. 
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Figure 1.1 2,5-diketopiperazine structural derivatives 
 
13a catalyzed hydrocyanation product enantio purity was as good/comparable as 
enzyme catalysed (D-Oxynitrilase) hydrocyanation product.8, 10, 11 
 
 
 
Scheme 1.6 Chiral hydro cyanation of aromatic aldehydes 
 
Danda et al.12 studied the viscosity related property ‘Thixotropy’ influence in the 
enantioselective hydrocyanation of 3-phenoxybenzaldehyde 15 (Scheme1.7) employing 
the peptide catalyst 13b (Figure 1.1). In this work, reaction maintained a clear gel state 
when dipeptide catalyst 13b was rapidly crystallized prior to use. The amorphous solid 
gave both high enantioselectivities and catalytic activities. When 13b was prepared as a 
crystalline solid or needles, the state of the reaction was observed as a slightly opaque 
gel or a suspension. Under these conditions, the enantioselectivity and catalytic 
activities were significantly diminished. The influence of thixotropy on the 
enantioselectivity was demonstrated by showing that faster rates of stirring translated 
into increased enantioselectivities. Monitoring the physical properties of the gelled 
reaction mixture showed that the viscosity decreased as a function of increased stirring 
rate.  
 
 
Scheme 1.7 Thixotropy property was examined in this reaction 
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Several groups13 approached to elucidate the mechanism of this hydrocyanation 
reaction but, thirty five years after the first report of catalytic hydrocyanation, a clear 
understanding of the reaction mechanism of the catalyst 13a remains elusive. Lipton 
and co-workers, in 1996 reported the use of catalyst 13c (Figure 1.1) which is a slight 
modification of 13a, accelerated proton transfer in the Strecker reaction of 
benzaldimines 16 (Scheme 1.8). Lipton14 considering the basicity of the histidine side 
chain in 13a was insufficient to accelerate proton transfer, replaced the imidazole ring 
in 13a with the more basic guanidine which provided competent catalyst for Strecker 
reaction. 
 
 
Scheme1.8 Addition of HCN to benzaldimines 
 
1.2.2.2 Aldol reactions 
 
Nature has provided aldolases of Type I and Type II whereby Type I proceeds through 
an enamine pathway and the second via the co-ordination of Zn (II) ion (Figure 1.2). In 
view of enamine catalysis, a great deal of attention has been paid to peptide catalysed 
asymmetric aldol reaction, one of the most important carbon-carbon bond forming 
reactions.  
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Whereas proline and its derivatives can be applied as small and rigid organocatalysts 
for this transformation, nature uses to some extent the metal-free type I aldolase for 
this task. In both cases, the mechanism is based on enamine formation.15 With the 
purpose to associate the best properties of the two systems; many research groups 
focused their work on the development of peptidic catalysts for asymmetric aldol 
reactions. In 2003 Reymond et al.16 documented first peptide catalysed aldol reaction 
between p-nitrobenzaldehyde17 and acetone. In this report several classes of peptides 
(Scheme 1.9, Figure 1.3) were investigated. Both class IA and IB involve primary amines 
whereas class IIA and IIB contain secondary amines. Among the examined peptides, the 
class IIB catalysts displaying N-terminal prolines as the secondary amine component 
emerged as the superior class of catalysts under the reaction conditions investigated.  
 
 
Scheme 1.9 First peptide catalysed asymmetric aldolraction 
 
 
 
 
Figure 1.3 Different class of peptide catalysts employed in aldol reaction 
 
 
 
 
Scheme 1.10 List tri and di-peptide catalysed aldol reaction 
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Martin and List17 showed that di 18a-b and tri peptides 19a-d could be used as efficient 
aldol-promoting catalysts (Scheme1.10). In 2004 Gong and workers documented18 the 
regioselective direct aldol reaction between hydroxy acetone 20 and electron deficient 
aromatic aldehydes (Scheme 1.11). Among the di, tri, tetra, penta and hexa peptides 
examined, the tetra peptide 21 showed excellent promises for the controlled formation 
of regioisomer 22 as the major adduct. Interestingly, the major product in L-proline19 or 
aldolase catalysed analogous reactions provided the alternative regioisomer. Kudo and 
co-workers20 studied N-terminal prolyl peptide catalysts immobilized on PEG-PS for the 
direct aldol reaction in aqueous medium. The peptide catalyst H-D-Pro-Tyr-Phe-(PEG-
PS) in the presence of ZnCl2 (additive) improved the product enantio-selectivity and 
catalyst was recycled with minimal loss of activity. 
 
 
Scheme1.11 Peptide catalysed asymmetric regio selective direct aldol reaction 
 
Wennemers et al.21 established an excellent general strategy ‘catalyst-substrate co-
immobilization’ strategy for testing the members of combinatorial split-and-mix 
libraries for catalytic activity applications in bimolecular reactions (Figure 1.4). Using 
this concept, Wennemers group developed reactive peptidic organocatalysts 23 and 24 
for aldol reactions (Scheme 1.12).  
 
 
Figure 1.4 Wennemer’s catalyst-substrate co-immobilization strategy: Compound 2 
catalyses the reaction between A and B resulting in the covalent attachment of the dye on 
the corresponding bead. 
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This work demonstrated the value of small peptides as catalysts in various reactions, 
and also solved the difficulty in the rational design of catalytically active peptides.22 The 
combinatorial method is ideally suited for the testing of peptides-as well as libraries of 
other small molecules-and could accelerate the discovery of peptides that are able to 
catalyse synthetically important reactions. In the aldol reaction of acetone with various 
aldehydes (Scheme 1.12)1 mol % of catalyst 23 efficiently provided the (S)-product, 
whereas 10 mol % of catalyst 24 gave the (R)-product in up to 91% enantiomeric 
excess. Interestingly, catalyst 23 provided(R) product whereas 24 afforded (S)-product 
with neo-pentane aldehyde as substrate.  Many research groups introduced wide range 
of peptides for direct aldol reaction of acetones, cyclic ketones, hydroxyl acetone with 
aromatic or aliphatic aldehydes.23 
 
 
 
Scheme 1.12 Wennemers 23 and 24 catalysed aldol reaction of acetone with aldehydes 
 
1.2.2.3 Michael or 1,4-conjugate addition reactions 
 
 
Scheme1.13 (25), (26) catalysed Michael addition of ketones onto nitroolefins 
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Martin and List 17 documented the peptides that could catalyse the addition of acetone 
to trans-βnitrostyrene. Then Cordova24 examined several small peptides 25 and 26 for 
the asymmetric 1,4-addition of cyclic ketones to trans nitro olefins 27 (Scheme 1.13). 
Wennemers and co-workers26 documented the tri-peptides (Scheme 1.14) H-D-Pro-Pro-
Asp-NH2 (23)25 H-D-Pro-Pro-Glu-NH2 that differs only by a methylene group. Both 
catalysts were employed in the 1,4-asymmetric Michael addition of aldehydes to various 
trans nitro olefins. Interestingly, both peptides efficiently catalysed reactions with ≥1 
mol % in presence of 1 mol % NMM [N-methylmorpholine] as an additive. The catalytic 
reactivity and product stereoselectivity of tripeptide 23 was greater than 28. 
 
 
 
Scheme 1.14 Asymmetric 1,4-addition of buteraldehyde to nitro olefin 
 
These studies not only revealed the significance of the D-Pro-Pro residues as turn 
inducing element for high catalytic activity, but also provided insight into functional and 
structural features of this type peptide catalysts, whereby both a secondary amine and a 
carboxylic acid are required for effective catalysis.  
 
 
Scheme1.15 Conjugate addition of azide to carbonyl compounds. 
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Miller and co-workers27 demonstrated β-turn peptides 29 possessing τ–(benzyl)-His 
residue act as good catalysts (up to 85% ee) for the conjugate addition of azides to α,β-
unsaturated compounds 30 (Scheme 1.15). 
1.2.2.4 Addition of nitroalkanes to α,β-unsaturated carbonyl compounds 
Tsogoeva and Jagtap28 examined peptides 31 (H-Leu-His-OH) and 32 (H-His-Leu-OH) in 
the addition reaction of 2-nitropropane to cyclohexenone in presence of (1R, 2R)-1,2-
diphenylenediamine 33 as an additive (Scheme 1.16). In later publication of Tsogoeva et 
al.29 arginine peptides 34a, 34bb and  di-35a, tri-35b, and tetrapeptides 35c were 
screened in the Michael addition of nitroalkanes to cyclic α,β-unsaturatedcarbonyl 
compounds in the presence of additives such as trans-2,5-dimethylpiperazine 36. This 
study revealed the efficacy of peptides as catalysts than simple amino acids, and catalyst 
loading was reduced from 30 mol % to 5 mol %. Acyclic compounds containing all 
carbon, quaternary stereocenters represent a class of challenging molecules for 
asymmetric synthesis. Kudo30 used helical peptide 37 for the conjugate addition 
(Scheme 1.17a) of nitro methane 38 to β,β-disubstituted aldehydes 39 to generate 
compounds 40 with the newly formed all carbon stereo centre. 
 
 
Scheme 1.16 Conjugate addition of nitroalkane to unsat. carbonyls 
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Wennemers etal.31 achieved same type of γ-nitroaldehydes 42 (up to 97% ee) with 
consecutive stereogenic centres using peptide 41 (Scheme 1.17b). 
 
 
 
 
 
 
Scheme 1.17 Peptide catalysed conjugate addition reactions providing quaternary   
stereocentre 
 
1.2.2.5 Morita-Baylis-Hillman reaction 
Morita-Baylis-Hillman (MBH) reaction was first documented by Mortia32a in 1968, 
which was patented32b in 1972 by Baylis and Hillman. MBH reaction is a powerful C-C 
bond forming reaction whose multi-step mechanism allows numerous possibilities for 
catalyst intervention.33 There are many recent contributions to peptide mediated 
asymmetric MBH reaction from various research groups.34 Miller’s35 group 
demonstrated that a combination of peptides as catalysts and single amino acids as co-
catalyst could be applied in the asymmetric Morita-Baylis-Hillman reaction of methyl 
vinyl ketone 43 with aromatic aldehydes 44.  
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Scheme 1.18 Miller's catalyst 45 induced Morita-Baylis-Hillman reaction 
 
Among the π-(Me)His (Pmh)peptides examined, the octamer 45 was found to be the 
most efficient organocatalyst furnishing the product 46 in 78 % enantiomeric excess 
(Scheme 1.18). Same group reported36 a new pyridyl alanine based catalyst 47 for the 
asymmetric addition of allenoates 48 to N-acyl imine derivatives 49 which gave adduct 
50 in 88% yield with around 95% ee (Scheme 1.19). Exploration of the structure-
activity relationship (SAR) of each position of the peptide by single substitution led to a 
peptide that could catalyze the Morita-Baylis-Hillman reaction in 61% ee. At this point, a 
direct relationship was observed between peptide length and selectivity.  
 
Scheme 1.19 47 catalysed allenoate aza-Morita-Baylis-Hillman reaction 
 
The correlated increase in selectivity that was observed with increasing main chain 
length levelled off at the stage of an octamer peptide 45, which catalyzed the Morita-
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Baylis-Hillman reaction in 78% ee, these findings helped in better understanding of 
peptide catalysis and expanded the field of peptide-based catalysts.  
 
1.2.2.6 Asymmetric epoxidations 
Chiral epoxidation is one of the most powerful and widely used organic 
transformations. Epoxides are common structural features in many useful natural 
products and biologically active compounds. In addition, epoxide ring-opening with a 
large variety of nucleophiles could generate required stereocentres. Julia and co-
workers9 documented the discovery of asymmetric epoxidation. In the publications of 
Julia and Colonna, the influence of the reaction conditions, the effects of solvent, 
temperature, and oxidizing agent and catalyst structure such as length of peptide chain 
were thoroughly and systematically examined. Itsuno documented37 the use of poly-
amino acids on a solid support cross-linked amino methylated polystyrene (CLAMPS) 
resin for the application to asymmetric epoxidation reactions. It was found that poly-L-
leucine 51 was the excellent catalyst for the epoxidation of chalcones. In addition, the 
catalyst can be recovered and reused for up to 12 cycles with 94 % ee of product 10 
(Scheme 1.20). On the other hand, the original poly-amino acids are difficult to recycle 
as they take on a gel-like form.  
 
 
 
Scheme 1.20 Itsuno's CLAMPS for asymmetric epoxidation reaction 
 
Oxidizing agent38 was gradually improved in later studies from H2O2/NaOH to urea/ 
H2O2 and then to sodium percarbonate. Substrate scope41 in epoxidations was keenly 
examined which provided wider application than the original Julia-Colona publication 
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on this reaction. Peptides on solid-support39 also served as good catalysts for the 
epoxidation of α,β-unsaturated carbonyl compounds. Miller group39a documented 
peptide 52 catalysed epoxidation. Tanaka39b extensively investigated the peptide 
structures by X-ray crystallographic analysis, which revealed the relationship between 
the helical structures and enantiomeric excesses and this analysis provided knowledge 
to remodel the peptide catalysts for highly enantioselective epoxidation of α,β-
unsaturated ketones .  
 
Scheme 1.21 Polymer supported peptides in asymmetric epoxidation 
 
In 2011, Kudo40 reported first highly enantioselective epoxidation employing resin-
supported peptide 53 (Scheme 1.21). In recent times,41 the advances in enantioselective 
peptide and organocatalysed epoxidations have been particularly evident and in 
synthetic chemistry, new and useful methods for enantioselective epoxidations have 
been under continuous development. 
 
1.2.2.7Asymmetric hydrogen transfer reactions 
List et al.42 reported first metal-free catalytic transfer hydrogenation reaction in 2004 in 
this report α,β- unsaturated aldehydes 54 were converted to saturated aldehydes 54a 
using dibenzylammoniumtrifluoroacetate 55 as catalyst in presence of Hantzsch ester 
56. Later many groups documented hydrogenation of nitroolefins43 cyclic enones44 
quinolones45 using various organocatalysts. Kudo et al. documented46 highly 
enantioselective asymmetric hydrogenation of aromatic α,β- unsaturated aldehydes in 
aqueous media using PEG-PS-supported peptidecatalyst 57 which afforded enantio 
purity up to 96% (Scheme 1.22).   
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Scheme 1.22 Asymmetric hydrogen transfer reaction 
 
1.2.2.8 Kinetic resolution by peptides 
Separation of two enantiomeric substrates from a racemic (1:1) mixture in a reaction 
using chiral reagent is known as kinetic resolution. This type of resolution is an 
important and yet challenging task in chemical synthesis. Few of such reactions were 
discussed below which used peptides as chiral agents. 
1.2.2.8.1 Resolution by bromination 
Isomerism exhibited by molecules with restricted bond rotation is termed 
atropisomerism and the compounds that contain chiral axes, which exist about bonds 
with restricted rotation, are known as atropisomers. Resolving these isomers is one of 
the most challenging tasks in synthetic chemistry. Miller and co-workers10,47 
documented successful dynamic kinetic resolution of biaryl atropisomers 58 by their 
bromination 59 in 2010. Peptide 60 was used in the brominaton of  biphenols to resolve 
atropisomers with excellent selectivities (up to 94% ee) (Scheme 1.23). 
 
 
Scheme 1.23 Miller’s kinetic resolution of biaryl atropisomers by bromination 
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Scheme 1.24 Enantioseletive bromination of N,N-diisopropylbenzamides 
 
These researchers48  also employed peptide 61 for the enantioselective bromination of 
N,N-disubstituted benzamides 62 and observed the spontaneous enantiomeric 
enrichment of one atropisomer 63 (Scheme 1.24). 
1.2.2.8.2 Resolution by acylation 
Miller and co-workers examined various peptides49 for selective acylation reactions 
(See Scheme 1.4). Same group tackled challenging kinetic resolution50 of meso-diols 64 
with peptide 65 (Scheme 1.25). This peptide could discriminate the two alcohol 
functionalities and selectively acylated one alcohol to give 66 in 80% yield. 
 
 
Scheme 1.25 Desymmetrization by selective acylation using peptide 
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1.3 Conclusions and outlook 
Over the last fifteen years, peptides have been proven as flexible alternatives to 
enzymes and other small organic catalysts for a remarkable range of various reactions. 
Peptides modular nature facilitates for altering of their catalytic activities. This 
modularity permitted the designing of peptide catalysts with high stereo-selectivities, 
reactivities, as well as with regio- and chemo selectivities.  Peptide catalysis work in 
general discloses that short chain peptides can certainly function as asymmetric 
catalysts but the low catalytic activity persists a major challenge in most instances. In 
summary, combined with the ease of large scale synthesis of peptides, in particular 
small and medium size peptides, several catalysts are attractive for applications in 
organic synthesis and even on an industrial scale for example Singh’s catalyst.51 
 
1.4 Research objectives 
Asymmetric C-C bond formation is one of the most fundamental transformations in 
chemical synthesis. Despite numerous metal-based and enzymatic strategies that have 
been developed over the years to construct C-C bond, continuous demand for 
improvement stimulates the search for new methods, which utilize readily available, 
inexpensive, environmentally friendly materials. The recently established field of 
organocatalysis has supplied new devices for enantioselective C-C bond forming 
reactions, providing solutions to long standing challenges in synthesis. One such 
example is asymmetric conjugate addition of ketones to β-nitrostyrenes, reported early 
in 2000 by Barbas and co-workers.52 The reaction which was catalysed by (S)-proline, 
proceeded (Scheme 1.26) in high yield and diastereoselectivity, albeit gave nearly 
racemic products. 
 
Scheme 1.26 The(S)-proline catalysed addition of cyclohexanone to nitrostyrene 
 
Later, Enders53 demonstrated that methanol instead of DMSO was beneficial to the 
enantioselectivity of the addition reaction. After these reports there has been great 
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interest, shown by many researchers in designing new organocatalysts to improve the 
stereo-selectivities and chemical yields. Chandrasekhar et al. also developed, 1,2,3-
triazole-based proline organocatalysts54 (Figure 1.5) for asymmetric C-C bond forming 
aldol and Michael addition reactions. Establishment of 1,2,3-triazoles as amide bond 
surrogates (refer section 2.1) encouraged us to design and investigate  peptide based 
triazole catalysts for the Michael addition reaction.  
 
 
The goal of this Ph.D. work was to develop efficient, easily accessible, and environmentally 
benign peptide based organocatalysts for the enantioselective Michael addition reaction. 
In particular, proline-triazole derivatives were envisioned to provide a suitable catalytic 
platform. It was also anticipated that, triazole can act as a backbone to the peptide and 
therefore lead to the rigid conformations of peptides, which may give good selectivities. 
Over the course of this work, a further goal became the investigation of the mechanism 
and rationalization of the stereochemistry of the Michael products by computational 
investigations of the reaction intermediates. 
Many 1,2,3-triazole containing chemical entities were observed biologically active and 
some of them showed promising anti-fungal and anti-bacterial properties.  
 
Figure 1.6 Diazepinomicin natural product and its core skeleton 
  
Furthermore, they were also proved as anti-cancer agents however, there are only few 
triazole containing molecules which entered clinical trials for example cephalosporin 
Chapter I 
 
20 | P a g e  
 
antibiotic cefatrizine, β-lactam antibiotic tazobactam (inhibits the action of bacterial β-
lactamase) and calcium channel blocking anti-cancer compound carboxyamidotriazole55 
69 (Figure 1.6). In continuation of triazole work, it was also planned to synthesize 
hybrid derivatives of triazole, by combining it with dibenzodiazepinone 70 which is the 
key structural element of diazepinomycin71 (Figure 1.6). Diazepinomycin is a natural 
product which showed in vivo activity in mouse model against breast and prostate 
gliomatumors. Therefore, the second goal of this Ph.D. work was to develop novel potent 
anti-cancer agents, it was anticipated that, combination of two pharmacophores, triazole 
and dibenzodiazepinone could result in hybrid chemical scaffolds with good anti-cancer 
and/or other biological properties. 
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2.1 Introduction 
In recent years, a variety of organocatalysts and reaction conditions has been reported 
for enamine catalysed asymmetric conjugate addition of aldehydes or ketones to 
different Michael acceptors and this has been an attractive method for carbon-carbon 
bond formation. Various Michael acceptors were reported including nitrostyrenes,1 
enones,2 and vinylsulfones3 or alkylidene malonates.4 In particular, trans-β-nitrostyrene 
can function as a reactive electrophile and is therefore an attractive Michael acceptor. 
Initial studies1 of the L-proline catalysed 1,4-addition of cyclohexanone to β-
nitrostyrene (Scheme 2.1) revealed that this reaction proceeds smoothly to furnish the 
Michael adduct in high yield and diastereoselectivity. However, a catalyst loading of 15 
mol% was required and the observed enantioselectivity remained low (23 % ee). This 
first report highlighted the need for more optimised catalysts which can address the 
drawback of activity and stereo selectivity of such reactions. From the emergence of 
organocatalysis in chemical synthesis, many research groups have designed and 
employed a diverse range of organocatalysts for the Michael-addition reaction. 
Recently, small and medium peptides have been utilized as organocatalysts.5 Our work 
on peptidomimetics and turninducing properties of the unusual β-amino acids6 inspired 
the design and synthesis of the new peptide based triazole compounds 1 and 1a (Figure 
2.1) which potentially could exhibit improved organocatalytic properties. Heterocyclic 
moieties like 1,2,3-triazoles, 1,2,4-oxadiazoles, and 1,3,4-oxadiazoles have been proven 
as amide bond surrogates or ester and amide bond isosteres.7 In these transoid amide 
bond surrogate heterocyclic rings, 1,2,3-triazole ring  incorporation into peptidomimics 
has become facile via the introduction of ‘click’ chemistry. The simple construction of 
the 1,2,3- triazole ring can be achieved using the copper catalysed azide alkyne 
cycloaddition (CuAAC) reaction or ruthenium catalysed azide alkyne cyclo addition 
(RuAAC) reaction. In recent years a significant number of reports described the 
insertion of the1,2,3-triazole ring in β-turn mimics.8  
 
Scheme 2.1 Proline catalysed asymmetric Michael addition reaction 
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We conceived that a triazole ring as an amide bond surrogate could adopt a rigid 
backbone conformation and thus promote product stereoselectivity. We further 
anticipated that the enhanced number of nitrogen atoms would also have an influence 
on the basicity of the catalysts. An additional amino-acid appendage as proposed by 
Wennemers et al.9 was anticipated to provide hydrogen bonding with substrates.  
 
 
Figure 2.1 1,5 and 1,4 substituted triazole peptide catalysts 
 
With this background, we initiated the synthesis of pyrrolidine-linked triazoles having 
an iso-asparagine amino acid appendage by the retrosynthetic strategy depicted in 
Scheme 2.2. 
2.2 Retrosynthesis of 1 and 1a 
In the retrosynthetic approach (Scheme 2.2) catalyst (1/1a) was disconnected at the 
amide bond which could be constructed through coupling of acid (can be obtained from 
ester 2/2a) and amine (A).  
 
Scheme 2.2 Retrosynthetic route for the proposed catalysts 
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Further, the ester (2/2a) was disconnected via click transformation into alkyne 
ethylpropiolate and azide 3 which can be further easily synthesized from L-proline. 
2.3 Synthesis of 1 and 1a 
Azide 3 was synthesized from the readily available L-proline,10 by sequentially 
protecting the secondary amine with t-butyloxy carbonyl (Boc) in the presence of di-
tert-butyl-dicarbonate (Boc)2O and sodium bicarbonate in 98% yield; reduction of the 
acid to alcohol (86% yield) with borane dimethyl sulphide complex in THF(dried over 
Na-metal) solvent at 0 ᵒC and further transformation of the alcohol into the tosyl 
derivative; and finally, the heating of the tosylate in DMF at 80 ᵒC for 12 h with sodium 
azide produced the product (Scheme 2.3). Formation of azide group was evident from 
the [M+H]+ peak at 227 in the ESIMS and the absorption band at 2095 cm-1 in the  IR 
spectrum. Then, synthesis of catalysts 1 and 1a commenced with the thermal Huisgen 
[3 + 2] cycloaddition reaction11 of azide 3 and ethylpropiolate in toluene which 
rendered the easily separable triazole ester isomers 2a and 2 in 72:28 ratios with 91% 
yield. 1,5-substituted triazole ester 2 was faster than the 1,4-substituted triazole ester 
2a in thin layer chromatography (TLC). These two triazole esters also showed different 
physical properties. Compound 2 is a viscous liquid whilst 2a is a colourless solid. Both 
compounds 2 and 2a were also synthesized individually in Ru and Cu catalyzed click 
reactions respectively.  
 
 
Scheme 2.3 Synthesis of triazole esters 2 and 2a 
 
2.3.1 The Ru catalysed [3+2] cycloaddition of ethylpropiolate and (3) to triazole 
ester (2) 
Single isomer 2 (1,5-substituted) was prepared by a ‘Ru’ catalyzed cycloaddition12 
reaction. The azide 3 and ethylpropiolate were allowed to react in presence of 
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Cp*RuCl(PPh3)2 in dry benzene at 80 ᵒC under Argon. The column chromatography 
purification of the crude product on silica gel afforded triazole ester 2 as a viscous liquid 
in 70% yield (Scheme 2.4). The structure of compound 2 was further confirmed by 1H 
NMR where the ethyl ester and the triazole proton corresponding peaks were observed 
at δ 4.48 (quartet), 1.45 (triplet), and 8.10 singlet   respectively. 
 
 
Scheme 2.4 Ru catalysed synthesis of 1,5-substituted triazole ester 2 
 
Product formation also evident from the mass spectrometric analysis, where the peak 
corresponding to the mass of the parent ion was observed at m/z 347 [M+Na]+ 
2.3.2 Cu catalysed click or [3+2] cyclo addition reaction for the synthesis of 2a 
Triazole ester 2a was also constructed employing Cu-catalysed ‘click’ reaction (Scheme 
2.5).  Azide 3 and ethylpropiolate were subjected to ‘click’ reaction11 conditions using 
hydrated copper sulfate and sodium-ascorbate in tert-butanol/H2O (1:1) which 
produced after silica gel column chromatography 2a as a colourless solid in 85% yield. 
A singlet peak at δ 8.03, quartet at δ 4.43 and triplet at δ 1.41 in 1H NMR confirmed the 
formation of the product. In addition, the ion peak at m/z 347 corresponding to [M+Na]+  
in the mass spectrum further confirmed the product characterization as 2a.  
 
 
Scheme 2.5 Cu catalysed synthesis of 1,4-substituted triazole ester 2a 
 
2.3.3 General synthetic procedure for the preparation of 1 and 1a 
Having synthesized two triazole esters 2 and 2a, a common procedure was utilized to 
prepare 1 and 1a. The triazole esters were hydrolysed using the base mono hydrated 
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LiOH in THF/H2O (7:3) which furnished the respective acids. These solid acids (80% 
crude compound yield) were washed with n-hexane three times, concentrated on the 
rotary evaporator and directly used for the next reaction (Scheme 2.6 and 2.7). The 
obtained acids were coupled with amine A (aspartamine) following a general EDCI, 
HOBt coupling method which yielded both 4, 4a as solids in 80% and 85% respective 
yields. Formation of the peptide bond was confirmed by amide proton signal at δ 8.03 
for 4 8.21 for 4a respectively in 1H NMR. 
 
 
Scheme 2.6 Synthesis of 1,5- substituted triazole compound 1 
The observed molecular ion peaks corresponding to the [M+H]+ at m/z 501.2457 for 
compound 4 and at m/z 501.2455 for compound 4a in the  high resolution mass 
spectrum further confirmed the identity of the product.  
 
 
Scheme 2.7 Synthesis of 1,4-substituted triazle  1a 
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The benzyl ester group in 4 and 4a was successfully converted to the acid 5 (95% yield) 
and 5a (96% yield) in the presence of 10% palladium-carbon and hydrogen gas 
(balloon) conditions in methanol solvent. Conversion of ester to acid was evident from 
disappearance of aromatic proton signals and singlet signal at δ 4.26 (4) and δ 5.16 (4a) 
corresponding to benzyl protons in 1HNMR spectrum. In next step the t-butyloxy-
carbonyl (Boc) protecting group was removed with trifluoroaceticacid in 
dichloromethane (1:1) at room temperature that rendered the TFA salts of catalysts 1 
and 1a. These were then washed 5-6 times with n-pentane and fully dried in vacuo 
giving both catalysts in 88% yield. Both the catalysts were characterized by 1H and, 13C 
NMR, HRMS, and IR analysis. 
2.4 Conclusion 
Two triazole based peptide compounds i.e 1,5-sustituted triazole compound 1 and 1,4-
substituted triazole compound 1a have been efficaciously prepared. The key steps 
involved a thermal Huisgen [3+2] addition reaction, Cu and Ru catalyzed azide-alkyne 
cycloaddition reactions, and general acid-amine coupling reactions. These two 
compounds were prepared with the expectation that they would exhibit effective 
catalytic activity in asymmetric Michael addition transformations.  
2.5 Experimental Section 
2.5.1 General Experimental conditions 
All reagents and solvents were of commercial grade purchased and used without 
further purification. Melting points of the compounds were recorded using Electro 
thermal melting point apparatus after column chromatography and were uncorrected. 
1H NMR (300/500 MHz) and 13C NMR (75/125 MHz) spectra were recorded in CDCl3 or 
CD3SOCD3, or CD3OH or D2O solvents on Bruker Avance 300 MHz or INOVA 500 MHz 
spectrometer at ambient temperature. Chemical shifts (δ) were reported in ppm 
downfield from internal TMS standard. Signal multiplicities are represented by s 
(singlet), d (doublet), t (triplet), dd (double doublet), m (multiplet) and br s (broad 
singlet). HRMS results were run on the AB Sciex QSTAR ELITE orQSTAR XL hybrid 
MS/MS mass spectrometer using an electron spray ionization ESI source. The optical 
rotations were recorded on ANTON PAAR MCP-200 digital polarimeter. IR spectra were 
recorded on Perkin-Elmer Infrared spectrometer; samples were ground with KBr and 
run by diffused reflectance accessory. Routine monitoring of reaction was performed by 
TLC (Thin layer chromatography) on aluminium silica plates obtained from E-Merck. 
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For TLC visualisation UV light and iodine were used. All the column chromatographic 
separations were done by using silica gel (Acme’s, 60-120 mesh). Evaporation of 
solvents was performed at reduced pressure in a rotary evaporator. 
2.5.2 (S)-N-tert-Butyl 2-(hydroxymethyl)pyrrolidine-1-carboxylate  
 
To a solution of Boc-protected proline acid (10 g, 46.5 mmol) in dry THF (50 mL) at 0 ᵒC 
was added a BH3 in dimethylsulfide (10M 5.1mL,51.1 mmol) and stirred for 4 h at room 
temperature. After total consumption of the acid (by TLC), the solvent was removed 
from reaction mixture using a rotary evaporator in a fume hood. Then the residue was 
quenched with water at 0 ᵒC and extracted with EtOAc (3 x 50 mL), washed with brine 
(50 mL), dried over anhydrous Na2SO4 and concentrated under vacuum to yield the 
crude product, which was purified by silica gel (60-120 mesh) column chromatography 
(hexanes/EtOAc, 3:7) to afford product the Boc protected prolinol (8.3 g, 89% yield) as 
a viscous solid.  
[α]D25: −47.2 (c 1.3, CHCl3); IR(νmax):3430, 2979, 2872, 1662, 1479, 1455, 1401, 1366, 
1341, 1254, 1164, 1128 cm-1; 1H NMR (300 MHz, CDCl3): δ4.83 (br s, 1H, -OH), 4.01-3.82 
(m, 1H), 3.66-3.53 (m, 2H), 3.49-3.39 (m, 1H), 3.37-3.26 (m, 1H), 2.03-1.93 (m, 1H), 
1.90-1.72 (m, 2H), 1.64-1.53(m, 1H), 1.47 (s, 9H, -O(CH3)3); 13C NMR (75 MHz, CDCl3): 
δ156.8, 79.9, 67.0, 59.8, 47.3, 28.4, 28.2, 23.8; ESIMS: m/z 202 [M+H]+. 
2.5.3 (S)-N-tert-Butyl-2-(tosyloxymethyl)pyrrolidine-1-carboxylate  
 
To a solution of the above Boc-protected prolinol (5.0 g, 24.8 mmol) in CH2Cl2 (30 mL) 
was added Et3N (3.8 mL, 27.3 mmol) and re-crystalized p-toluenesulfonyl chloride (5.1 
g, 27.3 mmol) at 0 ᵒC and allowed to stir for 3-4 h at ambient temperature. After 
completion of the reaction, the reaction mixture was quenched with saturated aqueous 
NH4Cl and extracted with CH2Cl2 (3 x 20 mL). The combined organic layers were 
washed with water (20 mL), brine (20 mL), dried with anhydrous Na2SO4 and 
concentrated in vacuo. The residue was purified by silica-gel (60- 120 mesh) column 
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chromatography (hexanes/EtOAc, 9:1) to afford tosylated alcohol (7.5 g, 86% yield) as 
colourless oil.  
[α]D25 : −36.8 (c 1.2, CHCl3); IR (νmax): 2975, 2882, 1689, 1598, 1391, 1361, 1255, 1172, 
1096, 966, 906, 812, 664 cm-1; 1H NMR (CDCl3, 300 MHz): δ7.77 (d, 2H, J = 8.1 Hz, ArH), 
7.35 (d, 2H, J = 6.2 Hz, ArH), 4.15-4.04 (m, 2H, -O-CH2-), 4.01-3.85 (m, 1H, ), 3.38-3.22 
(m, 2H), 2.44 (s, 3H, para-CH3), 1.98-1.69 (m, 4H), 1.39 (s, 9H, -O(CH3)3); 13C NMR 
(CDCl3, 75 MHz): δ153.6, 144.6, 132.5, 129.6, 127.5, 69.7, 60.1, 55.2, 46.5, 28.0, 23.4, 
22.5, 21.2; ESIMS: m/z 356 [M+H]+; HRMS Calcd for C17H26NO5S 356.1102, found 
356.1108. 
2.5.4 (S)-N-tert-butyl-2-(azidomethyl)pyrrolidine-1-carboxylate (3) 
 
To the tosylated alcohol (5.0 g, 14 mmol) in 60 mL of DMF was added sodium azide (4.5 
g, 70 mmol) and heated at 80 ᵒC with reflux condenser for 12 h. The reaction mixture 
was allowed to cool to room temperature and then the product was extracted with 4X50 
mL diethyl ether; the combined organic layers were washed with ice-cold water, 50 mL 
brine, dried over anhydrous Na2SO4 and concentrated on rotary evaporator (crude yield 
72%, 2.23 g). Azide 3 was used as such for the next reaction. Formation of azide group 
was evident from [M+H]+ peak at 227 in ESIMS and absorption band at 2095 cm-1 in IR 
spectroscopy. IR (νmax): 2975, 2879, 2095, 1689, 1478, 1387, 1247, 1162, 1126, 1104, 
856, 773 cm-1 
2.5.5 (S)-N-Ethyl1-((1-(tert-butoxycarbonyl)pyrrolidin-2-yl)methyl)-1H-1,2,3-
triazole-5-carboxylate(2) and (S)-N-ethyl-1-((1-(tert-butoxycarbonyl)pyrrolidin-
2-yl)methyl)-1H-1,2,3-triazole-4-carboxylate (2a) 
To a solution of 3 (3.5 g, 15.4 mmol) in toluene (60 mL) was added ethyl propiolate (4.5 
g, 46.4 mmol) (Scheme 2.2) The mixture was heated to reflux for 19 h, after cooling to 
room temperature, the solvent was removed and the two isomers were separated by 
silica gel column chromatography, furnishing 3.31 g (66%) of 2a and 1.25 g (25%) of 2 
as waxy solid and viscous oil respectively in yield 91%. 
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2.5.5.1 Ru-catalyzed click reaction 
 
To the azide 3 (4.0 g, 17.6 mmol) and ethyl propiolate (5.2 g, 53.0 mmol) in dry benzene 
(30 mL) was added catalytic amount (0.281 g, 2 mol %) of Cp*RuCl(PPh3)2 under argon 
atmosphere and resulting mixture was stirred at 80 ᵒC. After complete consumption of 
the starting materials, mixture was filtered, solvent was removed in vacuo and residue 
was purified on silica gel column chromatography which yield triazole 2 (4.0 g, 70%). 
[α]D25 -9.5 (c 1.2, CHCl3); IR (νmax): 3132, 2977, 1731, 1696 cm-1; 1H NMR (CDCl3, 300 
MHz)δ: 8.10 (brs, 1H, triazole H), 4.83-4.70 (m, 2H, CHCH2-triazole), 4.48-4.31 (m, 3H, 
OCH2+CH), 3.68-3.23 (m, 2H, NCH2), 2.02-1.63 (m, 4H, (CH2)2), 1.45-1.30 (s+m, 12H, 
O(CH3)3+OCH2CH3); ESIMS: m/z 347 [M+Na]+. 
2.5.5.2 Cu- catalyzed click reaction 
 
To a solution of compound 3(4.0 g, 17.6 mmol) and ethyl propiolate (5.2 g, 53.0 mmol) 
in 20 mL tert-butanol was added aqueous solution of CuSO4·5H2O (1M, 5 mL) and 
sodium ascorbate (1M, 5mL). After stirring for overnight at room temperature, water 
(60 mL) was added and extracted with (3X50 mL) EtOAc. The combined organic layers 
were washed with 50 mL brine solution, dried over anhydrous Na2SO4, concentrated in 
vacuo. Column purification afforded a white solid (4.87g, 85 % yield).mp 85-87 ᵒC; 
[α]D25-65.2 (c 0.92, CHCl3); IR (Neat) 3132, 2978, 1739, 1723, 1693 cm-1; 1H NMR (300 
MHz, CDCl3: δ 8.05 (s, 1H, triazole H), 4.84-4.48 (m, 2H, CH-CH2triazole), 4.42 (q, J = 14.1 
Hz, 7.1 Hz, 2H, -OCH2-), 4.12 (br s, 1H, CH), 3.49-3.02 (m, 2H,NCH2), 2.09-1.65 (m, 4H, 
(CH2)2), 1.50 (s, 9H, -O(CH3)3), 1.41 (t, J = 7.1 Hz,  3H, -OCH2CH3); ESIMS: m/z 347 
[M+Na]+. 
2.5.6 (S)-N-tert-Butyl-2-((5-(((S)-1-amino-4-(benzyloxy)-1,4-dioxobutan-2-
yl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)pyrrolidine-1-carboxylate (4) 
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To the compound 2 (3.0 g, 9.2 mmol) in 20 mL of THF:H2O (7:3) was added base 
LiOH·H2O (1.1 g, 27 mmol) and allowed to stir at rt for 3 h. After completion of the 
reaction, the THF was removed in vacuo, diluted with 50 mL of water, 5-10 mL of ethyl 
acetate was added, layers were separated in separating funnel and organic layer was 
taken out to remove impurities. Aqueous layer was acidified (pH = 3) with solid KHSO4, 
extracted with ethyl acetate (2x60 mL), dried over anhydrous Na2SO4 and concentrated 
in rotary evaporator to get solid. This solid was then washed with n-hexane three times 
(3X5 mL) and dried in rotary evaporator to get solid acid (2.19 g, 80% crude), which 
was used as such for the next step. To the well dried acid (2.0 g, 6.17 mmol) in dry 
CH2Cl2 (15 mL) was added HOBt (0.91 g, 6.79 mmol) and stirred for 10 min.  EDCI (1.29 
g, 6.79 mmol) was added to the reaction mixture at 0 ᵒC and allowed to stir for another 
10 min. Then the amine A (1.37 g, 6.17 mmol) was added (pre basified with DIPEA, 
(2.68 mL, 15.43 mmol)) and the resultant mixture was allowed to stir at ambient 
temperature for 24 h. After consumption of the starting materials, the reaction was 
quenched with saturated aqueous NH4Cl and extracted with CH2Cl2. The organic layer 
was sequentially washed with saturated aqueous NaHCO3, brine solution, dried over 
anhydrous Na2SO4, concentrated in vacuo and the residue was purified by silica gel 
column chromatography to yield 4 as a white solid.  
Yield 80% (3.6 g); mp 80-82 ᵒC; [α]D25=-4.8 (c 1, MeOH); IR (υmax): 3402, 2973, 2926, 
1733, 1681, 1570, 1396, 1170, 771 cm-1;1H NMR (300 MHz, DMSO-d6) rotamers 
observed δ: 8.16 (d, J = 7.6 Hz, 1H, CONH-), 7.37 (s+s, 1H, triazole H), 6.64 (s, 1H, one of 
CONH2), 6.54-6.39 (m , 6H, ArH+one of CONH2), 4.26 (s, 2H, OCH2Ph), 4.04-3.76 (m, 3H, 
CHCONH2+-CH2triazole), 3.49-3.34 (brs , 1H, CH), 2.43-2.25 (m, 2H, NCH2), 2.18-2.06 
(rotamer , 1H, one of CH2COOBn), 1.95-1.81 (rotamer , 1H, one of CH2COOBn), 1.05-0.64 
(m , 4H, (CH2)2), 0.52-0.43 (s+s , 9H, O(CH3)3).13C NMR (75 MHz, DMSO-d6) δ: 171.0, 
169.7, 157.0, 153.0, 135.6, 133.9, 130.5, 127.9, 127.4, 127.5, 78.2, 65.3, 56.2, 55.4, 50.6, 
48.9, 45.4, 35.6, 27.5, 22.5, 21.6; HRMS (ESI): m/z calculated for [C24H33O6N6] 501.2456 
[M+H]+, found 501.2457. 
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2.5.7 (S)-4-Amino-3-(1-(((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)methyl)-1H-
1,2,3-triazole-5- carboxamido)-4-oxobutanoic acid (5) 
 
To compound 4 (2.5 g, 5.0 mmol) in methanol (6 mL) was added 10% Pd/C (53 mg 0.5 
mmol) under inert atmosphere. This was allowed to react under a H2 atmosphere for 
about 5-6 h. After completion of the reaction, the mixture was filtered through a pad of 
celite bed using methanol, concentrated in vacuo, and the resultant solid was purified 
through silica gel column chromatography (CHCl3: MeOH; 9:1) to give 5 as a fine white 
solid. 
Yield 95% (1.94 g); mp 98-101 ᵒC; [α]D25= -11.7(c 1, MeOH); IR (υmax): 3181, 2967, 2928, 
1691, 1569, 1396, 772 cm-1; 1H NMR (300 MHz, DMSO-d6) δ: 8.12 (br, 1H, triazole H), 
7.39 (s+s, 1H, CONH-), 6.59 (s, 1H, one of CONH2), 6.35 (s, 1H, one of CONH2), 4.00-3.78 
(rotamer , 3H, CHCONH2+-CH2triazole), 3.50-3.35 (brs, 1H, CH ), 2.40-2.22 (rotamer, 2H, 
NCH2), 2.04-1.89 (m, 1H, one of CH2COOH ), 1.84-1.63 (rotamer, 1H, one of CH2COOH), 
1.05-0.64 (m, 4H, (CH2)2,) 0.60-0.40 (s+s, 9H, O(CH3)3). 13C NMR (75 MHz, DMSO-d6) δ: 
171.6, 157.3, 153.3, 134.1, 130.9, 78.5, 56.4, 55.7, 50.9, 49.4, 45.6, 35.8, 27.8, 22.7, 21.8 
HRMS (ESI):m/z calculated for [C17H26O6N6Na] 433.1806 [M+Na]+, found 433.1800. 
2.5.8 (S)-4-Amino-4-oxo-3-(1-((S)-pyrrolidin-2-ylmethyl)-1H-1,2,3-triazole-5-
carboxamido)butanoic acid (1) 
 
To a suspensionof compound 5 (1.50 g, 3.6 mmol) in CH2Cl2 (5 mL) was added 
trifluoroacetic acid (5 mL) (CH2Cl2:TFA; 1:1) at 0ᵒC and then stirred at room 
temperature. The reaction was monitored by thin layer chromatography and after the 
completion of the reaction, CH2Cl2 was removed in vacuo. Excess trifluoroacetic acid 
was co-distilled with 5 mL of CH2Cl2, this process was repeated several times and 
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residue was finally washed with n- pentane, dried under vacuum to give compound 1 as 
a white solid.  
Yield 88% (0.99 g);mp 80-82 ᵒC; [α]D25 =+9.0 (c 1, CH3OH);IR (υmax): 3415, 1672, 1561, 
1200, 1137 cm-1; 1HNMR (300 MHz, D2O) δ: 8.22 (d, J = 8.3 Hz, 1H), 5.09 (dd, J = 14.9, 3.6 
Hz, 1H), -4.91 (m, 1H), 4.19-4.04 (m, 1H), 3.46-3.24 (m, 2H), 2.90-2.55 (m, 2H), 2.39-
2.24 (m, 1H), 2.24-1.77 (m, 4H); 13C NMR (75 MHz, D2O) δ: 175.9, 174.7, 158.3, 134.1, 
130.4, 58.9, 50.7, 49.2, 45.1, 37.2, 26.7, 21.9; HRMS (ESI): m/z calculated for 
[C12H19O4N6] 311.1462 [M + H]+, found 311.1460. 
2.5.9 (S)-tert-Butyl-2-((4-(((S)-1-amino-4-(benzyloxy)-1,4-dioxobutan-2-
yl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)pyrrolidine-1- carboxylate (4a) 
 
Compound 2a (4.0 g, 12.3 mmol) was treated with LiOH·H2O (1.59 g, 37 mmol) in 30 mL 
of THF:H2O (7:3) similarly to thatdescribed for the synthesis of 4, which gave a fine 
white solid (2.99 g, 82% crude). To this acid (2.93 g, 9.89 mmol) in dry CH2Cl2 (20 mL) 
was added HOBt (1.46 g, 10.88 mmol) at room temperature and stirred for 10 min 
under nitrogen gas. Then, to the reaction mixture was added EDCI (2.07 g, 10.88 mmol) 
at 0 ᵒC, allowed to stir at ice cold temperature for another 10 min. To this, β-benzyl L-
isoasparaginate (A) (2.19 g, 9.89 mmol) (Pre basified with DIPEA; 3.83 g, 29.69 mmol) 
was added and stirred for 24 h. The reaction was monitored by TLC, after total 
consumption of the starting materials, reaction was quenched with super saturated 
aqueous NH4Cl (30 mL) and extracted with CH2Cl2. Organic layer was given washings 
with saturated aqueous NaHCO3 (40 mL) and 30 mL brine solutions, dried over 
anhydrous Na2SO4, concentrated in vacuo and the residue was purified by column 
chromatography using hexane and EtOAc (2:8) to obtain 4a as a white solid. 
Yield 85% (4.19 g); mp 70-73 ᵒC; [α]D25 = -25.8 (c 1, MeOH);IR (υmax): 3348, 2976, 2885, 
1733, 1683, 1569, 1396, 1170, 771 cm-1;1H NMR (300 MHz, CDCl3) δ: 8.21 (d, J = 7.6 Hz, 
1H, CONH), 8.06 (s, 1H, triazole H), 7.40-7.29 (m, 5H, ArH), 6.62 (br s, 1H, one of 
CONH2), 5.84 (br s, 1H, one of CONH2), 5.16 (s, 2H, OCH2Ph), 5.11-5.03 (m, 1H, 
CHCONH2), 4.76-4.36 (m, 2H, CH2triazole), 4.19-4.08 (br, 1H, CH), 3.48-3.21 (m, 2H, 
CH2N), 3.22 (dd, J = 17.4, 4.5 Hz, 1H, CH2COOBn), 2.88 (dd, J = 16.6, 6.0 Hz, 1H, 
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CH2COOBn), 2.12-1.66 (m, 4H, (CH2)2), 1.49 (s, 9H, O(CH3)3); 13C NMR (75 MHz, CDCl3+ 
DMSO-d6) δ: 171.6, 170.1, 159.2, 153.9, 141.9, 134.8, 127.7, 127.3, 125.9, 79.4, 65.8, 
56.2, 52.1, 51.2, 48.3, 46.2,  35.5, 27.6, 22.6; HRMS (ESI): m/z calculated for [C24H33O6N6] 
501.2456 [M+H]+, found 501.2455. 
2.5.10 (S)-4-Amino-3-(1-(((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)methyl)-1H-
1,2,3-triazole-4-carboxamido)-4-oxobutanoic acid (5a) 
 
To 4a (2.0 g, 4.0 mmol) in methanol (8 mL) was added 10% Pd/C (42 mg 0.4 mmol) 
under nitrogen atmosphere and placed under a hydrogen atmosphere for about 4-5 h. 
After consumption of the starting material, the mixture was filtered through a short bed 
of celite using methanol, the solvent was removed on a rotary evaporator to attain the 
solid which was purified by column chromatography to obtain 5a as white solid. 
Yield 96% (1.58 g); mp 85-87 ᵒC; [α]D25 = -28.3 (c 1, MeOH);IR (υmax): 3701, 3082, 2908, 
1676, 1586, 773cm-1; 1H NMR (300 MHz, D2O)δ:8.44 (s, 1H, triazole H), 4.99-4.89 (m, 
1H, CHCONH2), 4.70-4.55 (m, 1H), 4.37-4.30 (m, 2H), 3.45-3.28 (m, 2H, CH2N), 3.09-2.88 
(m, 2H, CH2COOH), 2.12-1.78 (m, 4H, (CH2)2), 1.41- 1.07 (s+s,9H, O(CH3)3); 13C NMR (75 
MHz, CDCl3+DMSO-d6) δ: 171.5, 158.6, 153.2, 141.2, 125.6, 78.6, 55.6, 51.4, 50.6, 47.9, 
45.6, 27.1, 21.9;HRMS (ESI): m/z calculated for [C17H27O6N6 ] 411.1986 [M+H]+, found 
411.1982. 
2.5.11 (S)-4-Amino-4-oxo-3-(1-((S)-pyrrolidin-2-ylmethyl)-1H-1,2,3-triazole-4-
carboxamido) butanoic acid (1a) 
 
To a suspension of 5a (1.50 g, 3.6 mmol) in CH2Cl2 (5 mL) was added trifluoroacetic acid 
(5 mL) CH2Cl2:TFA (1:1) at 0 ᵒC and stirred at room temperature and the reaction was 
monitored by thin layer chromatography. After completion of the reaction the 
dichloromethane was removed in vacuo. Excess trifluoroacetic acid was co-distilled 
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with 5 mL of CH2Cl2, this process was repeated several times, and residue was finally 
washed with n- pentane and dried under vacuum to get compound 1a as solid. 
Yield 88%  (1.0 g); mp 179-181 ᵒC; [α]D25 = +28.8 (c 1, MeOH);IR (υmax): 3391, 1676, 
1571, 1200, 1134 cm-1;1H NMR (300 MHz, D2O) δ: 8.52 (s, 1H, triazole H), 4.94-4.87 (m, 
2H), 4.20-4.04 (m, 1H, ), 3.49-3.27 (m, 2H), 3.11-2.88 (m, 2H), 2.31-2.12 (m, 1H), 2.21-
1.76 (m, 4H, (CH2)2);13C NMR (75 MHz, D2O) δ: 174.1, 173.9, 160.7, 140.7, 126.9, 58.4, 
49.5, 49.1, 45.0, 35.2, 26.6, 21.8 HRMS (ESI): m/z calculated for [C12H19O4N6] 311.1462 
[M+H]+, found 311.1460. 
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3.1 Introduction 
The asymmetric Michael addition reaction is one of the most significant and widely 
practiced C-C bond-forming reactions for the construction of optically pure highly 
functionalised carbon skeletons for the total synthesis of natural and biologically active 
compounds. Its strategic importance is evident by considering that a Michael addition 
can represent the initiating step of more complex inter- and intra-molecular tandem 
processes.1 The asymmetric C-C bond forming organo-catalyzed Michael addition 
reactions (Scheme 3.1) have advanced in recent years and now pave the way for a new 
era in asymmetric synthesis.2 Due to the simplicity of the asymmetric organocatalytic 
approach,3 the Michael addition of various donors and acceptors has been studied using 
various organo-catalysts. Common Michael donors include ketones, aldehydes, α-hetero 
substituted ketones, cyclic ketones, α,α-disubstituted aldehydes and dioxanone.  
Michael acceptors include β-nitrostyrenes, β-nitroacrolein dimethyl acetals, 
alkylidenemalonates, chalcones, vinyl ketones and vinyl sulfones.2p-t The strong 
electron-withdrawing ability of nitroolefins makes them attractive Michael acceptors 
among the other Michael acceptors and enabling the nitro group in the product to be 
converted into other functionalities.  Nitro groups can undergo a Nef reaction,4 
reductions to an amino group,5 the Meyer reaction6 and the conversion into a nitrile 
oxide.7 
 
 
3.2 Applications of Michael adducts 
As mentioned above, the nitro group in 4 can be easily transformed into other 
functionalities. Several research groups have attempted the synthesis of the Reissig 
nitrone8 5 shown in Scheme 3.2 from the Michael adduct. In 2006, Maleczka, Jr.9 
reported the reduction of various aromatic and aliphatic nitro groups with Pd-catalyzed 
silicon hydride in the synthesis of nitrone 5 from 4 (Scheme 3.2). Similar conversions 
were reported by Tang et al.10 using Pd/C catalyst hydrogenation in MeOH solvent with 
92% product enantiomeric selectivity and yield 95%. 
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Several other research groups11 also reported the construction of nitrones from Michael 
adducts. In 2011 Chen and co-workers12 successfully constructed poly functionalized 
bicyclic[4.4.0]decalin skeletons 7 (Scheme 3.3) from Michael adducts using the TMS 
prolinol organocatalyst 6. These bicyclic skeletons are important intermediates for the 
synthesis of biologically active compounds13  and naturally occurring diterpenoids.14 
 
 
3.3 Screening experiments with 1 and 1ain 1,4-asymmetric Michael addition 
reactions 
3.3.1 Optimisation of a model Michael addition reaction 
3.3.1.1 Solvent screening and catalyst loading selection 
Various solvents were screened in the 1/1a induced Michael addition reaction. 
Cyclohexanone was selected as the Michael-donor and β-nitrostyrene as Michael-
acceptor (Scheme 3.4). The temperature was kept constant [at room temperature] and 
the catalyst loading was varied from 5 mol % to 0.1 mol % which afforded diverse yields 
and enantiomerically pure products.  
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Firstly, the reaction was carried out with 5 mol % of 1/1a, 1 equivalent of β-
nitrostyrene and 5 equivalents of ketone cyclohexanone in various solvents (Scheme 
3.4; Table 3.1). The catalysts afforded different optical purities in different solvents. 
Product 4 was characterized with 1H (Figure 3.1) and 13C-NMR spectroscopy and mass 
spectral analysis. In 1H-NMR appearance of two dt signals at δ 3.75 and 2.63 
corresponding to chiral protons and two dd signals at δ 4.94 (J = 4.4, 12.4 Hz), 4.43 ( J = 
10.0, 12.4 Hz) corresponding to pro-chiral protons indicated the formation of the 
Michael adduct. Mass spectral data further confirmed the formation of the product with 
a molecular ion at m/z 270 [M+Na]+. To determine the optical purity of the obtained 
Michael product, chiral HPLC was performed using Daicel Chiralpak IA column and for 
reference, a racemic Michael adduct synthesized using (DL)-proline. 
 The yields with the both catalysts varied from 55% in dichloromethane (Table 3.1, 
entry 1) to 96% in isopropanol (Entry 12), 80% to 94% (Entry 1 and 11) diastereomeric 
excess (de) and 82% to ≥99% (Entry 2 and 1) enantiomeric excess (ee) was observed. 
Isopropanol and methanol solvents were observed to be the best solvents. On the other 
hand, with water as the solvent, 98% optical product purity (ee) was obtained however 
with lower yields, when compared with isopropanol and methanol. Interestingly, when 
the reaction performed in absence of the solvent, a good yield, de as well as ee was 
obtained (Entry 7&8). The screening information for other solvents is presented in 
Table 3.2. When the amount of catalyst loading was reduced to 2 mol % in the same 
reaction, the results in all solvents were surprisingly very similar. When the catalyst 
mol% was reduced to 1 mol %,  0.5 mol % and 0.1 mol %,( Table 3.3) the progress of the 
reaction with 1 using 0.5 mol % was good but, with 0.1 mol %, the reaction was very 
slow and had not even begun after three days.  
Figure 3.1 
1
H NMR spectrum of Michael adduct 4 (CDCl
3
 300 MHz) 
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Table 3.1 Solvent effect in 5 mol % 1/1a catalysed Michael addition reactions 
 
 
Table 3.2 Solvent effect in 2 mol % 1/1a catalysed Michael addition reactions 
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Table 3.3 Solvent effects in 1 &0.5 mol % 1/1a catalysed Michael addition reactions 
  
In conclusion, despite no obvious trend in solvent effect on reaction, the optimal solvent 
and catalyst loading for the reaction were found to be methanol and 0.5 mol % 
respectively. 
3.3.1.2 Crossover experiments 
To ensure that the observed peaks in chiral HPLC chromatogram were that of the 
Michael adducts, a series of model experiments were performed wherby a racemic 
Michael product was made using (DL)-proline catalyst (reactants: cyclohexanone and β-
nitrostyrene) and same Michael adduct obtained using catalyst 1 or 1a  (Scheme 3.1). 
Two products wereseperately analysed in a chiral HPLC  column to obtain the 
chromatogram (see Figure 3.2 racemic and chiral Michael adducts’ chromatograms). 
Then, a small amount of racemic Michael product was added to the chiral Michael 
adduct. This mixture sample was also run on the same chiral HPLC column, as expected, 
the optical purity of the mixture (racemic + chiral Michael adduct)  was diminished.  
Evidently, the enantiomeric excess of chiral Michael adduct (90% ee ) was reduced to 50 
% ee due to the addition of racemic compound. Thus, the peaks observed in chiral HPLC 
chromatogram of 1/1a induced Michael addition product were not other impurities. 
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Figure 3.2 Chiral HPLC chromatograms of crossover experiments 
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3.3.1.3 Additive screening experiments 
In many organocatalysed reactions, various acids including benzoic acid, n-butyric 
acid15 acetic acid16 etc. and bases such as NMM17 DMAP, imidazole etc. were used as co-
catalysts. Phenols and water were also used as additives in various transformations. It 
has been proposed that the additives or co-catalysts activate the enone and thereby 
reduce the C-C bond formation barrier with this activation proceeding through a 
hydrogen-bonding interaction with the carbonyl group.  It is also commonly considered 
that acids are able to increase the rate of the overall catalytic process by accelerating 
the formation of the enamine and/or its hydrolysis. Some research groups have 
provided computational models to examine the effect of co-catalysts in organocatalytic 
reactions.18 When water is present in large excess,19 this results in the lowering of the 
product enantiomeric purity from 76 % to 30 %. The reason for this has been attributed 
to water molecules interrupting the ionic interactions and the H-bonding critical for the 
transition states that lead to the high selectivities.   
 
Table 3.4 Additive screening in Michael addition reaction 
 
On the other hand, water has been shown20 to enhance product regioselectivity, 
affording products with 91% to 99% ee. There is no doubt that the use of additives 
increases the reaction rate, yield, and selectivity, however these outcomes are usually 
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substrate-dependant. In our experiments, the catalysts (1/1a) were used as the TFA 
salts of amines, in order to test whether any additive would influence/increase the 
product selectivity few additives were added to the 1/1a catalysed Michael addition 
reaction (Table 3.4). In the event, none of the additives increased product selectivity or 
the yield. In fact, addition of co-catalysts resulted in lowering of stereoselectivities. In 
conclusion, acid additives did not improve the reaction yield or selectivity and thus, 
further reactions (see section 3.5 substrate scope) were conducted without any acid 
additives.   
3.3.1.4 Optimal reaction conditions 
From the screening experiments, the optimal reaction conditions were established for 
the Michael addition reaction. Methanol solvent and 0.5 mol % catalyst loading; were 
the optimal reaction conditions selected for the 1/1a mediated Michael addition 
reaction.  
3.4 Substrate scope 
The very low loading of the catalyst required, prompted us to explore potential wider 
applications of the catalyst activity on other substrates. Having the optimised conditions 
in hand, substrate generality of the 1 and 1a catalysed Michael addition reaction was 
explored. Various Michael acceptors that is, nitroolefins were examined under the 
optimised conditions.  Reactions were screened with 0.5 mol % catalyst loading, 1 
equivalent of nitro olefin and 5 equivalents of the Michael donor cyclohexanone in 
methanol at ambient temperature. Hetero aromatic (Table 3.5; entry 2&4) and 
substituted aromatic (Table 3.5, entry1, 3 and 5-10) nitro-olefins (3a-n) reacted with 
cyclohexanone in presence of catalysts 1/1a to give Michael-adducts (4a-n) in good 
yield and excellent diastereo and enantioselectivities. Electronic factors in the substrate 
appeared to have no effect on reaction selectivity. Electron withdrawing groups such as 
nitro (88% ee  with both the catalysts 1 and 1a), fluoro (92 and 90% ee with 1 and 1a 
respectively), trifluoromethyl (98 % ee (1) and 94%ee (1a)), and bromo (Entries 1,3,6, 
8 and 9) gave excellent stereoselectivities. On the other hand, nitroolefins with electron 
donating groups like methyl (92% (1) and 82 % (1a) ee), methoxy (82% (1) and 76% 
(1a) ee) and heterocyclic olefins also gave good optical purity but, relatively less 
selectivities than  nitroolefins with withdrawing groups (Entries 5, 7, 2 and 4).  
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Table 3.5 Substrate scope in 1/1a induced Michael addition reactions 
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aAll reactions were performed at room temperature in MeOH with 0.5 mol% loading of catalyst 1 and 1a; bIsolated 
yield after column chromatography. cBy HPLC; dBy chiral HPLC using chiralpak-IA column 250 x 4.6 mm; eThe 
stereochemistry of known compounds was confirmed by comparing optical rotation values with those reported in 
literature. 
 
Table 3.6 Substrate scope in 1/1a induced Michael addition reactions 
 
aAll reactions were performed at room temperature in MeOH with 0.5 mol% loading of catalyst 1and 1a; bIsolated 
yield after column chromatography. cDetermined by HPLC; dDetermined by chiral HPLC usingchiralpak-IA column 
250 x 4.6 mm; eDetermined by chiral HPLCchiralpak-IC; fThe stereochemistry of known compounds was confirmed 
by comparing optical rotation values with those reported in literature22,23,24. 
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Finally the other Michael donor ketones studied including acetone and 4-thiopyranone 
also provided products with moderate stereoselectivities and yields (Table 3.6). In 
conclusion, it is clear that there is no significance was associated with variations in the 
electron demand of the substrate groups. 
3.5 Computational studies of 1 and 1a 
After attaining the 0.5 mol% 1 and 1a catalysed Michael addition reaction, we were 
keen to explore further the molecular interactions of 1 and 1a hoping this would lead to 
an understanding of the catalysis mechanism. A detailed NMR investigation was under 
taken for both peptide catalysts to understand the turn pattern and hydrogen-bonding 
properties. Information on the preferred conformation of 1,5-triazole catalyst has been 
obtained at a concentration of approximately 5 mM in two independent structure-
supporting solvents: water (90% D2O + 10% H2O) and CD3OH, by using 1D and 2D (1H, 
COSY, TOCSY, and ROESY) NMR spectroscopic techniques. A significant number of intra-
residue H–H ROEs was observed for 1,5-triazole catalyst 1. Specifically, the observed 
unambiguous ROEs (Fig. 1a) for 110H-13H, 13H-(16Hi and 16Hj), 13H-17Hk, 14H-
16NHi, 10H-6Hh, 5H-6Hg, and 6Hg-2Hb were helpful in determining the conformation 
(Fig. 3.1a and Fig. 3.2).  
3.5.1 ROE-restrained molecular dynamics 
In order to delineate low-energy structures, ROE-restrained molecular dynamics 
studies have been carried out using simulated annealing protocol (insight II). Initially 
the input structures were rapidly heated from 300 K to 900 K, allowing the structure to 
remain at 300 K, 600 K and 900 K for 5 ps. The velocity-scaling temperature-controlling 
method was adopted for heating, and the temperature was allowed to vary by an order 
of 10 K. The velocity Verlet integration method was used for integration. The structures 
were then slowly cooled from 900 K to 300 K allowing the structures to remain for 5 ps 
at 800 K, 700 K, 600 K, 500 K, 400 K and 300 K. The cycle of simulated annealing was 
repeated 250 times, and the final structures were stored. Fifteen low-energy structures 
were selected from among the 250 conformations and superimposed. The structures 
predominantly showed a single conformation, which was a turn-like compact structure. 
A similar process was used for the 1,4-triazole catalyst 1a, shown in the Fig. 3.3b, and 
the results indicated that 1a adopts an extended conformation(Fig. 3.3b and Fig. 3.4), in 
contrast to 1. The detailed NMR investigations followed by ROE-restrained molecular 
dynamics established that the 1,5-disubstituted catalyst 1 adopts a relatively compact 
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turn-like conformation (Fig. 3.3a), whereas 1a with 1,4-disubstitution favoured an 
extended conformation (Fig. 3.3b).  Catalyst 1 ROESY spectrum also shown in the figure 
3.5. It was anticipated that the observed turn structure of the 1,5-triazolecatalyst 1 may 
favour its terminal iso-asparagine appendage to form a hydrogen bond with the nitro 
group of β-nitrostyrene leading to a stabilizing factor akin to that observed for D-Pro– L-
Pro–Asp–NH2, for an improved catalytic performance of the catalyst. 
 
 
 
Figure 3.3Transition state conformations of catalysts 1 and 1a 
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Figure 3.4 ROESY Spectrum of 1a in 500 l of 90% D2O and 10% H2O (700MHz, 298K) 
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Figure 3.5 ROESY Spectrum of 1 in 500 l of 90% D2O and 10% H2O (700MHz, 298K) 
 
3.6 Mechanistic insights of 1/1a induced Michael addition reaction 
In general, it has been proposed that secondary amines such as proline catalysed Aldol 
or Michael- addition reactions precede through either an iminium or enamine type of 
mechanism (Figure 3.6). Deeper insights put forth by several research groups, using 
computational studies and transition state models to understand the enamine 
mechanism have been invaluable.21 We examined the mechanism of cyclohexanone 
addition to β-nitrostyrene in presence of catalysts 1/1a using mass spectrometric 
methods. In the mass analysis of the progressing reaction m/z values of the product and 
enamine were found (Figure 3.7) at their corresponding mass values, that is, product 
mass 247 its [M+H] and [M+Na] peaks were observed at 248 and 270 m/z respectively. 
The enamine mass m/z 390 was also found as its [M+H]+ at m/z 391.  In addition, on the 
basis of DFT results, a mechanism is proposed to account for the observed stereo-
selectivity. The free acid of 1 behaves as a bifunctional catalyst. The proline ring first 
reacts with cyclohexanone carbonyl group to form an enamine with the help of acidic 
co-catalyst. Subsequently in the compact turn structure of 1, the proton of the terminal 
acid hydroxyl group interacts with the nitro group of β-nitrostyrene, through hydrogen 
bonding. 
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Figure 3.7 Mass spectral analysis report of progressing 1 induced Michael addition 
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The transition state involving the re-face attack on the anti-enamine (Figure 3.8) was 
lower in energy than other possible 25 transition states (anti-si, syn-re, and syn-si). 
Whereas in case of 1a there is no hydrogen-bond interaction between acid hydroxyl 
group of catalyst and nitro group of nitrostyrene to provide additional stabilization 
factor, so the 1a transition states are higher in energy than 1 (Table 3.7). 
3.6.1 DFT Studies- Computational Methods of Transition States 
DFT computations at the B3LYP/6-31G* level provided more insights into the catalytic 
activities of 1 and 1a. Standard protocols for observing transition states are followed, by 
using Gaussian 09 software. Initially, the fully relaxed minimum energy structures of 
1,5-triazole catalyst 1, 1,4-triazole catalyst 1a and β-nitrostyrene obtained from 
simulated annealing are subjected to optimization at B3LYP/6-31* level22 DFT 
calculations. The optimization was initially carried out in vacuum and then in MeOD 
solvent, by adopting PCM23 (Polarisable Continuum Model). These structures served as 
inputs (reactants) for computing transition state structures. The transition states for the 
addition of anti and syn enamine to the si and re faces of β-nitrostyrene were first 
located in the gas phase. These transition states are labelled a-re, a-si, s-re, and s-si. The 
noticeable charge separation in the transition state is expected upon addition of 
enamine to β-nitrostyrene. To obtain improved estimates of the reaction energetic 
continuum solvent effects are incorporated by computing the zero-point energies by 
using the PCM with methanol as the medium. The preferred transition-state structures 
arising from anti-enamine for both the catalysts 1 and 1a are depicted in Fig. 3.8 and 3.9 
Distances are in the angstrom units (Å). 
3.6.2 Possible stereo isomeric outcomes of Michael addition reaction 
From anti-enamine addition to re- face, si-face nitrostyrene results in the syn-(S,R) and 
anti-(S, S) stereoisomers respectively. Whereas,  syn-enamine addition to re- face, si-face 
nitrostyrene results in the anti-(R,R) and syn-(R, S) stereoisomers respectively (Figure 
3.10).  It was clear from the transition state energy calculations (Table 3.7) of 1 and 1a 
that, anti-enamine and re-nitro styrene combination resulted in minimum energy which 
in turn resulted in major isomer that is syn-(S,R) stereoisomer and anti-enamine and si-
nitroolefin resulted in minor isomer with anti-(S,S) stereochemistry. Stereochemistry of 
the products was determined by comparing optical rotation values reported in 
literature. 
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1-anti enamine+ re nitro styrene 
 
  
1-anti enamine+ si nitro styrene 
 
                                     Figure 3.8 Transition state study diagrams of catalyst 1 
 
 
 
 
 
 
 
 
Chapter III 
 
58 | P a g e  
 
 
 
 
 
 
  
1a-anti-enamine+ re nitro styrene 
 
 
 
1a-anti-enamine+si-nitro styrene 
 
Figure 3.9 Transition state study diagrams of catalyst 1a 
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Figure 3.10 Possible Michael adduct stereoisomers in the reaction   
 
Quantum mechanical calculations of the transition states for the addition of Anti 
and Synenamines to the siand re faces of nitrostyrene. Absolute Energies 
(HARTREE and kcal/Mol) ofall the Transition States calculated at DFT B3LYP/6-
31G* level of theory. 
Table 3.7 1 and 1a Enamine-nitrostyrene transition state energies 
Enamine+ 
Nitrostyrene 
Transition state energy 
(HARTREE) 
Transition state 
energy(kcal/Mol) 
anti- re1a -1844.551983 12.75 
anti-si -1844. 548347 15.07 
syn-re -1844.548473 15.29 
syn-si -1844.548767 15.17 
 
Enamine+ Nitro 
styrene 
Transition state 
energy(HARTREE) 
Transition state 
energy(kcal/Mol) 
anti- re 1 -1844.567544 2.43 
anti-si -1844.565963 3.42 
syn-re -1844.562234 5.83 
syn-si -1844.562155 5.88 
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3.7 Conclusion 
Prepared triazole containing peptides 1 and 1a has been systematically examined as 
organocatalysts in asymmetric Michael addition reaction. Firstly, Michael addition of 
cyclohexanone to β-nitro styrene was studied as a model reaction in presence of 1 and 
1a, varying reaction parameters like solvent and catalysts loading. Effect of examined 
acidic additives was not positive. Having optimised reaction conditions, the 1 and 1a 
induced Michael addition reaction was generalised to various Michael donors and 
acceptors. Both electron-donating and -withdrawing groups on β-nitro styrene had 
showed no difference on the stereo selectivity of the reaction. This confirmed the wider 
scope of the catalysts and the non-participation of the substituents or ring structure of 
the nitroolefin. A catalyst loading 0.5 mol % is not reported in asymmetric Michael 
addition reactions of cyclohexanone to β-nitroolefins (by the time this work published). 
However, organocatalytic transformations including Michael addition reaction with less 
than 2 mol% or 1 mol% catalyst loading were known.24 Employing low amounts of 
organo-catalyst in organic transformations is useful from an economic perspective and 
also low concentrations of catalysts in reaction may lower the undesirable effect of 
catalyst impurities in reaction. Further, mechanism of the reaction was established 
using mass spectrometry and DFT computational methods.  
3.8 Experimental section 
3.8.1 General procedure for Michael addition reaction with 0.5 mol % catalyst 
loading  
To the catalyst 1 (0.005 equiv/ 0.5 mol %) or 1a (0.005 equiv/ 0.5 mol %) (10 mg of 
Catalyst was dissolved in 2 mL of methanol and from this required quantity of catalyst 
was taken) in MeOH (0.3 mL) was added ketone (5.0 equiv), 1.5 mL of MeOH followed 
by nitro olefin (1.0 equiv) at room temperature. Reaction was typically monitored by 
TLC, after completion of the reaction compound was directly adsorbed on silica and 
product was isolated using EtOAc and hexane. Analytical high performance liquid 
chromatography (HPLC) was performed using Daicel Chiralpak IA and IC columns. 
3.8.2 General procedure for racemic Michael addition reaction with DL-Proline 
To DL-Proline (0.3 equiv, 30 mol %) in MeOH (0.3 mL) was sequentially added ketone 
(5.0 equiv) and nitro olefin (1.0 equiv) at room temperature. After completion of the 
reaction, crude material was column purified on silica using hexane and EtOAc. 
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3.8.3 Analytical information of compounds 4 and 4a-n 
3.8.3.1 (S)-2-((R)-2-Nitro-1-phenylethyl)cyclohexanone (4)25 
 
1H NMR (300 MHz, CDCl3) δ: 7.35-7.23 (m, 3H, ArH), 7.20-7.14 (m, 2H, ArH), 4.94 (dd, 
1H, J = 4.4, 12.4 Hz, Hca), 4.43 (dd, 1H, J = 10.0, 12.4 Hz, Hcb proton), 3.76 (dt, 1H, J = 9.6, 
4.4 Hz, Hb), 2.74- 2.64 (m, 1H, Ha), 2.52-2.34 (m, 2H, αCH2-tocarbonyl), 2.13-2.03 (m, 1H, 
-CH2), 1.83-1.50 (m, 4H, -CH2), 1.30-1.18 (m, 1H, -CH2); 13C NMR (75 MHz, CDCl3): 
δ212.0, 137.8, 129.0, 128.2, 127.9, 79.0, 52.6, 44.0, 42.8, 33.3, 28.6, 25.1; ESIMS: m/z 
270 [M+Na]+; HPLC: chiral pak-IA column, 210 nm, isopropanol / hexane = 5:95, 1 
mL/min,  used to determine % ee (for ee see Table 3.1). 
3.8.3.2 (S)- 2-((R)-2-Nitro-1-(3-nitrophenyl)ethyl)cyclohexanone (4a)25 
 
Reaction was performed with 30 mg (0.15 mmol) of nitroolefin 3a, 80 µL (0.78 mmol) 
of cyclohexanone and 40 µL of catalyst solution 1 or 1a following the general procedure. 
White solid;1H NMR (300 MHz, CDCl3) δ: 8.16-8.09 (m, 2H, ArH), 7.60-7.50 (m, 2H, ArH), 
5.02 (dd, J = 13.0 4.4, Hz, 1H, Hca), 4.71 (dd, J = 12.9,10.1 Hz,1H, Hcb), 3.96 (dt, J = 
9.8,4.4Hz, 1H, Hb), 2.78-2.70 (m, 1H, Ha), 2.55-2.36 (m, 2H, αCH2-tocarbonyl), 2.17-2.13 
(m, 1H, -CH2), 1.87-1.58 (m, 4H, -CH2), 1.36-1.16 (m, 1H, -CH2);HPLC: chiral pak-IA 
column, 210 nm, isopropanol/hexane = 8:92, 1.0 mL/min; with catalyst 1 Rt = 
23.81(major), 20.65 (minor), 94:6 er, syn/anti = 96:4; Yield: 52% (23 mg); [α]D25 = -
18.04 (c 2.6, CHCl3); with catalyst 1a Rt = 23.46 (major), 20.47 (minor), 94:6 er, syn/anti 
= 95:5; Yield: 50% (22 mg); [α]D25 = -16.08 (c 2.8, CHCl3). 
3.8.3.3 (S)- 2-((S)-1-(3-Methylthiophen-2-yl)-2-nitroethyl)cyclohexanone (4b) 
 
Reaction was performed with 30 mg (0.21 mmol) of nitroolefin 3b, 112 µL (1.0 mmol) 
of cyclohexanone and 66 µL of catalyst solution 1 or 1a following the general procedure. 
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Solid; m.p 87-89 oC; IR (υmax ): 2932, 1707, 1552, 1378, 1128, 756, 716 cm-1; 1HNMR 
(500 MHz, CDCl3) δ: 7.14 (d, J = 5.0 Hz, 1H, ArH), 6.75 (d, J = 5.0 Hz, 1H, ArH), 4.98 (dd, J 
= 12.5, 4.1 Hz, 1H, Hca), 4.49 (dd, J = 12.6, 10.3 Hz, 1H, Hcb), 4.18 (td, J = 3.8, 9.8, 14.4 Hz, 
1H, Hb), 2.62-2.55 (m, 1H, Ha), 2.50-2.44 (m, 1H, α-CH2-tocarbonyl), 2.42-2.34 (m, 1H, -
CH2), 2.18 (s, 3H, -CH3), 2.15-2.08 (m, 1H, -CH2), 1.88-1.78 (m, 2H, -CH2), 1.74-1.55 (m, 
2H, -CH2), 1.31-122 (m, 1H, -CH2); 13C NMR (125 MHz, CDCl3) δ: 211.6, 136.5, 134.4, 
130.0, 123.2, 79.5, 54.0, 42.7, 37.3, 32.9, 28.6, 25.1, 13.8; HRMS (ESI):m/z calculated for 
[C13H17NNa O3S] 290.0821 [M+Na]+, found 290.0826; HPLC: chiral pak-IA column, 210 
nm, isopropanol/hexane = 5:95, 1.0 mL/min, with catalyst 1 Rt = 16.42 (major), 18.93 
(minor), 93:7 er, syn/anti = 90:10; Yield: 72% (41 mg);[α]D25 = -28.0 (c 1, CHCl3); with 
catalyst 1a Rt =15.44 (major), 17.91(minor), 89:11 er, syn/anti = 88:12;Yield: 69% (39 
mg); [α]D25  = -30.0 (c 1, CHCl3). 
3.8.3.4 (S)-2-((R)-1-(3-(Benzyloxy)phenyl)-2-nitroethyl)cyclohexanone (4c) 
 
Reaction was performed with 30 mg (0.11 mmol) of nitroolefin 3c, 60 µL (0.58 mmol) of 
cyclohexanone and 36 µL catalyst solution 1 or 1a following the general procedure. 
Solid; m.p 126-128 oC; IR(υmax ) : 2935, 2360, 1706, 1507, 825 cm-1;1HNMR (500 MHz, 
CDCl3) δ: 7.45-7.31 (m, 6H, ArH), 7.25-7.21 (m, 1H, ArH), 6.89-6.85 (m, 1H, ArH), 6.78-
6.75 (m,1H, ArH), 5.03 (s,2H, Ph-CH2-), 4.91 (dd, J = 12.5, 4.4 Hz, 1H, Hca),4.60 (dd, J = 
12.6, 10.0 Hz, 1H, Hcb),3.72 (td, J = 4.4, 9.9, 14.3 Hz, 1H, Hb), 2.66-2.59 (m, 1H, Ha), 2.49-
2.43 (m, 1H, α-CH2-to carbonyl), 2.40-2.32 (m, 1H, -CH2), 2.11-2.04 (m, 1H, -CH2), 1.80-
1.48 (m, 3H, -CH2), 1.23-1.16 (m, 1H, -CH2); 13C NMR (125 MHz, CDCl3) δ: 211.8, 158.9, 
139.3, 136.6, 129.9, 128.5, 127.9, 127.5, 120.6, 115.2, 113.6, 78.7, 70.0, 52.4, 43.8, 42.7, 
33.1, 29.6, 28.4, 25.0;HRMS (ESI):m/z calculated for [C21H23NNaO4] 376.1519 [M+Na]+, 
found 376.1542; HPLC: chiral pak-IA column, 210 nm, isopropanol/hexane = 5:95, 1.0 
mL/min, with catalyst 1 Rt = 21.85 (major), 17.29 (minor), 87:13 er, syn/anti = 
97:3;Yield: 72% (29 mg);[α]D 25 = -24.0 (c 1, CHCl3); with catalyst 1a Rt = 21.84 (major), 
17.26 (minor), 84:16 er, syn/anti = 93:7;Yield: 68% (28 mg); [α]D 25 = -13.0 (c 1, CHCl3). 
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3.8.3.5 (S)-2-((S)-1-(Furan-2-yl)-2-nitroethyl)cyclohexanone (4d)25 
 
Reaction was performed with 30 mg (0.21 mmol) of nitroolefin 3d, 110µL (1.0 mmol) of 
cyclohexanone and 66 µL of catalyst solution 1 or 1a following the general procedure. 
Yellow liquid;1HNMR (300 MHz, CDCl3) δ: 7.37 (s, 1H, ArH), 6.30-6.27 (m, 1H, ArH), 6.18 
(d, J = 3.2 Hz, 1H, ArH), 4.83-4.75 (m, 1H, Hca), 4.70-4.63 (m, 1H, Hcb), 4.01-3.93 (m, 1H, 
Hb), 2.80-2.71(m, 1H, Ha), 2.50-2.32 (m, 2H, α-CH2-tocarbonyl), 2.15-2.08 (m, 1H, -CH2-), 
1.87-1.56 (m, 4H,-CH2-), 1.32-1.24(m, 1H, -CH2-); HPLC: chiral pak-IA column, 210 nm, 
isopropanol/hexane = 7:93, 1.0 mL/min, with catalyst 1 Rt = 11.45 (major), 14.42 
(minor), 79:21er, syn/anti = 97:3;Yield: 68% (34 mg); [α]D25 = -4.31 (c 0.85, CHCl3); with 
catalyst 1a Rt = 11.56 (major), 14.48 (minor), 75:25 er, syn/anti = 94:6;Yield: 65% (33 
mg); [α]D25 = -4.00 (c 0.8, CHCl3). 
3.8.3.6 (S)-2-((R)-2-Nitro-1-(p-tolyl)ethyl)cyclohexanone (4e)25 
 
Reaction was performed with 30 mg (0.18 mmol) of nitroolefin 3e, 90 µL (0.92 mmol) 
of cyclohexanone and 57 µL catalyst solution 1 or 1a following the general procedure. 
1HNMR (300 MHz, CDCl3) δ: 7.12 (d, J= 7.5 Hz, 2H, ArH), 7.04 (d, J = 8.3 Hz, 2H, ArH), 
4.91(dd, J = 12.0, 4.5 Hz, 1H, Hca), 4.60 (dd, J= 12.0, 9.8 Hz, 1H, Hcb), 3.72 (dt, J= 9.8, 4.5 
Hz, 1H, Hb), 2.66 (dt, J= 11.3, 5.2 Hz, 1H, Ha), 2.52-2.34 (m, 2H, α-CH2-to carbonyl), 2.31 
(s, 3H, Ph-CH3), 2.13-2.02 (m, 1H, ), 1.82-1.50 (m, 4H), 1.31-1.15 (m, 1H); HPLC: chiral 
pak-IA column, 210 nm, isopropanol/hexane = 5:95, 1.0 mL/min, with catalyst 1Rt = 
12.47 (major), 10.31 (minor), 96:4er,syn/anti = 94:6; Solid;Yield: 64% (30 mg); [α]D25 = 
-22.0 (c 0.5, CHCl3); with catalyst 1a Rt = 12.50 (major), 10.31 (minor), 91:9er, syn/anti 
= 93:7;Yield: 60% (28 mg); [α]D25 = -20.4 (c 0.54, CHCl3). 
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3.8.3.7 (S)-2-((R)-1-(4-Fluorophenyl)-2-nitroethyl)cyclohexanone (4f)25 
 
Reaction was performed with 30 mg (0.17 mmol) of nitroolefin 3f, 92 µL (0.89 mmol) of 
cyclohexanone and 55 µL catalyst solution 1 or 1a following the general procedure. 
1HNMR (500 MHz, CDCl3) δ:7.35-7.24 (m, 2H, ArH), 7.03-6.86 (m, 2H, ArH), 4.95 (dd, J = 
12.6, 4.3 Hz, 1H, Hca), 4.61 (dd, J= 12.6, 10.0 Hz, 1H, Hcb), 3.78 (dt, J = 9.8, 4.3 Hz, 1H, Hb), 
2.65 (dt, J = 12.4, 4.9 Hz, 1H, Ha), 2.54- 2.31 (m, 2H, α-CH2-to carbonyl), 2.16-2.01 (m, 
1H, -CH2-), 1.86-1.50 (m, 4H, -CH2-), 1.36-1.17 (m,1H, -CH2-);HPLC: chiral pak-IA 
column, 210 nm, isopropanol/hexane = 5:95, 1.0 mL/min, with catalyst 1 Rt = 16.20 
(major), 14.19 (minor), 96:4 er, syn/anti = 93:7; Solid; Yield: 65% (30 mg);[α]D25 = -12.6 
(c 1.2, CHCl3); with catalyst 1a Rt = 16.02 (major), 14.04 (minor), 95:5 er, syn/anti = 
95:5;Yield: 60% (28 mg); [α]D25 = -12.0 (c 1.2, CHCl3). 
3.8.3.8 (S)-2-((R)-1-(4-Methoxyphenyl)-2-nitroethyl)cyclohexanone (4g)28,29 
 
Reaction was performed with 30 mg (0.16 mmol) of nitroolefin 3g, 86 µL (0.83 mmol) of 
cyclohexanone and 51 µL catalyst solution 1 or 1a following the general procedure. 
1HNMR (500 MHz, CDCl3) δ: 7.08 (d, J= 8.6 Hz, 2H, ArH), 6.85 (d, J = 8.4 Hz, 2H, ArH), 
4.91 (dd, J= 12.2, 4.5 Hz, 1H, Hca), 4.58 (dd, J = 12.2, 10.0 Hz, 1H, Hcb), 3.87 (s, 3H,-OCH3), 
3.77-3.66 (m,1H, Hb), 2.64 (dt, J = 11.1, 4.7 Hz, 1H, Ha), 2.54-2.31 (m, 2H, α-CH2-to 
carbonyl), 2.14-2.01 (m, 1H, -CH2-), 1.83-1.50 (m, 4H, -CH2-), 1.31-1.15 (m, 1H, -CH2-); 
HPLC: chiral pak-IA column, 210 nm, isopropanol/hexane = 5:95, 1.0 mL/min, with 
catalyst 1Rt = 18.49 (major), 15.29 (minor), 91:9er, syn/anti = 95:5;White solid; Yield: 
71% (32 mg); [α]D25 = -18.2 (c0.4, CHCl3); with catalyst 1a Rt = 18.52(major), 15.28 
(minor), 88:12er, syn/anti = 94:6;Yield: 65% (30 mg); [α]D25 = -16.1 (c0.41, CHCl3).  
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3.8.3.9(S)-2-((R)-2-Nitro-1-(4 (trifluoromethyl)phenyl)ethyl)cyclohexanone(4h)29 
 
Reaction was performed with 30 mg (0.13 mmol) of nitroolefin 3h, 71 µL (0.69 mmol) 
of cyclohexanone and 42 µL of catalyst solution 1 or 1a following the general procedure. 
1HNMR (300 MHz, CDCl3) δ: 7.59 (d, J= 7.5 Hz, 2H, ArH), 7.32 (d, J= 8.3 Hz, 2H, ArH), 4.98 
(dd, J = 12.0, 3.7 Hz, 1H, Hca), 4.75-4.64 (m, 1H, Hcb), 3.86 (dt, J = 9.8, 4.5 Hz, 1H, Hb), 
2.77-2.64 (m, 1H, Ha), 2.55-2.31 (m, 2H, α-CH2-to carbonyl), 2.18-2.00 (m, 1H, -CH2-), 
1.87-1.50 (m, 4H, -CH2-), 1.36-1.16- (m, 1H, -CH2);HPLC: chiral pak-IA column, 210 nm, 
isopropanol/hexane = 6:94, 1.0 mL/min, with catalyst 1 Rt = 28.53 (major), 13.54 
(minor), 99:1 er, syn/anti = 95:5; White Solid;Yield: 70% (30 mg); [α]D25 = -27.4 (c 0.4, 
CHCl3); with catalyst 1a Rt = 28.40 (major), 13.54 (minor), 97:3 er, syn/anti = 93:7; 
Yield: 67% (29 mg); [α]D25 = -26.2 (c0.41, CHCl3). 
3.8.3.10 (S)-2-((R)-1-(3-Bromophenyl)-2-nitroethyl)cyclohexanone (4i)28 
 
Reaction was performed with 30 mg (0.13 mmol) of nitroolefin 3i, 68 µL (0.66 mmol) of 
cyclohexanone and 41 µL of catalyst solution 1or 1a following the general procedure. 
1HNMR (500 MHz,CDCl3) δ:7.42-7.39 (m,1H, ArH),7.33 (t,J = 1.8 Hz, 1H, ArH),7.21-7.18 
(m, 1H, ArH), 7.14-7.11 (m,1H, ArH), 4.94 (dd, J = 12.8,4.4 Hz, 1H, Hca), 4.61 (dd, J = 12.8, 
9.9 Hz, 1H, Hcb), 3.74 (dt, J = 9.7, 4.4 Hz, 1H, Hb), 2.69-2.62 (m, 1H, Ha), 2.51-2.31 (m, 2H, 
α-CH2-to carbonyl), 2.14- 2.07 (m, 1H, -CH2-), 1.84-1.57 (m, 4H, -CH2-), 1.30-1.20 (m, 
1H, -CH2-);HPLC: chiral pak-IA column, 210 nm, isopropanol/hexane = 5:95, 1.0 
mL/min, with catalyst 1 Rt = 14.49 (major), 13.63 (minor), 82:18 er, syn/anti = 90:10; 
Solid;Yield: 66% (28 mg);  [α] D25 = -28.0 (c 1, CHCl3); with catalyst 1a Rt = 14.45 
(major), 13.59 (minor), 68:32 er, syn/anti = 81:19;Yield: 60% (25 mg);  [α]D25 = -25.0 (c 
0.98, CHCl3). 
 
3.8.3.11 (S)-2-((R)-1-(Anthracen-9-yl)-2-nitroethyl)cyclohexanone(4j)  
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Reaction was performed with 30 mg (0.12 mmol) of nitroolefin 3j, 62 µL (0.60 mmol) of 
cyclohexanone and 37 µL of catalyst solution 1 or 1a following the general procedure. 
Solid; m.p 199-201 oC; IR (υmax ): 2934, 1707, 1554, 1215, 758 cm-1;1H NMR (500 MHz, 
CDCl3) δ: 8.55 (d, J = 9.0 Hz, 1H), 8.43 (s, 1H), 8.07 (d, J = 8.4 Hz, 1H), 8.00 (d, J = 8.4 
Hz,1H), 7.91 (d, J = 8.9, Hz,1H), 7.61-7.46 (m, 4H), 5.76-5.70 (m, 1H), 5.20 (dd, J = 13.4, 
4.6 Hz, 1H), 5.11 (dd, J = 13.1, 7.3 Hz, 1H), 3.49 (dt, J = 5.3, 11.6 Hz, 1H), 2.63-2.57 (m, 
1H), 2.48 (dt, J = 6.1, 13.3 Hz, 1H), 2.10-2.01 (m, 1H), 1.72-1.52 (m, 3H), 1.52-1.49 (m, 
1H), 1.38-1.23 (m, 1H); 13C NMR (125 MHz, CDCl3) δ: 212.0, 131.9, 131.7, 131.6, 130.6, 
130.4, 129.3, 129.3, 128.6, 126.9, 126.3, 125.2, 124.6, 124.0, 123.5, 79.8, 53.3, 42.7, 36.3, 
33.3, 28.3, 25.2; HRMS (ESI): m/z calculated for [C22H21NNaO3] 370.1414 [M+Na]+, 
found 370.1420; HPLC: chiral pak-IA column, 210 nm, isopropanol/hexane = 8:92, 1.0 
mL/min, with catalyst 1 Rt = 22.02 (major), 15.33 (minor), 95:5 er, syn/anti = 
94:6;Yield: 73% (30 mg);   [α]D25 = -34.2 (c 1, CHCl3); with catalyst 1a Rt = 22.00 
(major), 15.33 (minor), 95:5 er, syn/anti = 97:3;Yield: 69% (28 mg);   [α]D25 = -32.0 (c 
1.09, CHCl3).    
3.8.3.12 (S)-3-((R)-2-Nitro-1-phenylethyl) dihydro-2H-thiopyran-4(3H)-one (4k)28 
 
Reaction was performed with 30 mg (0.20 mmol) of nitroolefin 3k, 70 mg (0.60 mmol) 
of dihydro-2H-thiopyran-4-one and 62 µL of catalyst solution 1 or 1a following the 
general procedure. 
Solid: 1H NMR (500 MHz, CDCl3) δ: 7.38-7.28  (m, 3H, ArH), 7.22-7.19 (m, 2H, ArH), 4.74 
(dd, J = 12.6 4.5 Hz, 1H, Hca), 4.63 (dd, J = 12.5, 9.6 Hz, 1H, Hcb), 3.98  (dt, J = 10.2, 4.5Hz, 
1H, Hb), 3.05 (dt,J = 9.7, 4.2 Hz, 1H, Ha), 3.01-2.96 (m, 2H, α-CH2- to carbonyl), 2.88-2.77 
(m, 2H, S-CH2), 2.59-2.64 (m, , 1H, S-CH2), 2.46 (dd, J = 9.3, 13.7 Hz, 1H, S-CH2);13C NMR 
(75 MHz, CDCl3) δ: 209.5, 136.4, 129.3, 128.3, 128.1, 78.6, 55.0, 44.5, 43.5, 35.1, 
31.6;HPLC: chiral pak-IC column, 210 nm, isopropanol/hexane = 10:90, 1.0 mL/min. 
with catalyst 1 Rt = 26.38 (major), 35.45 (minor), 93:7 er, syn/anti = 96:4; Yield: 70% 
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(37 mg);   [α]D25 = -24.6 (c 1, CHCl3); with catalyst 1a Rt = 26.41 (major), 35.43 (minor), 
89:11 er, syn/anti = 95/5;Yield: 66% (35 mg); [α]D25 = -26.2 (c 0.91, CHCl3). 
3.8.3.13 (S)-4-(3-Methylthiophen-2-yl)-5-nitropentan-2-one (4l) 
 
Reaction was performed with 30 mg (0.17 mmol) of nitroolefin3l, 130µL (1.77 mmol) of 
acetone and 55 µL of catalyst solution 1 or 1a following the general procedure. 
Viscous oil: IR (υmax): 2926, 1717, 1554, 1378, 758 cm-1; 1H NMR (300 MHz, CDCl3) δ: 
7.11 (d, J = 5.1 Hz, 1H, ArH), 6.77 (d, J = 4.9 Hz, 1H, ArH), 4.69-4.60 (m, 1H, ), 4.55-4.37 
(m,2H, ), 2.96-2.86 (m,2H), 2.25 (s, 3H, ArCH3), 2.13 (s, 3H, -COCH3);13CNMR (125 MHz, 
CDCl3) δ: 204.9, 135.3, 135.0, 130.4, 123.0, 79.6, 47.2, 32.8, 30.4, 13.7; HRMS (ESI): m/z 
calculated for [C10H13NNaO3S] 250.0508 [M+Na]+, found 250.0537;HPLC: chiral pak-IC 
column, 210 nm, isopropanol/hexane = 10:90, 1.0 mL/min, with catalyst 1 Rt = 16.96 
(major), 15.58 (minor), 68:32 er;Yield: 50% (20 mg); [α]D25 = -8.5 (c 1., CHCl3); with 
catalyst 1a Rt = 17.01 (major), 15.64 (minor), 65:35 er;Yield: 45% (18 mg); [α]D25 = -
11.0 (c 0.94, CHCl3). 
3.8.3.14 (R)-5-Nitro-4-phenylpentan-2-one (4m)27, 28 
 
Reaction was performed with 30 mg (0.20 mmol) of nitroolefin 3m, 147µL (2.01 mmol) 
of acetone and 62 µL of catalyst solution 1 or 1a following the general procedure. 
Solid;1HNMR (300 MHz, CDCl3) δ:  7.35–7.22 (m, 5H, ArH), 4.75–4.51 (m,2H, -CH2-NO2), 
4.05–4.00 (m, 1H, Ha), 2.94 (d, J = 6.6 Hz, 2H, Hb), 2.14 (s, 3H, -COCH3);HPLC: chiral pak-
IA column, 210 nm, hexane/isopropanol = 94:6, 1.0 mL/min, with catalyst 1 Rt = 12.19 
(major), 11.33 (minor), 68:32 er; Yield: 56% (23 mg); [α]D25 = -5.7 (c0.7, CHCl3); with 
catalyst 1a Rt = 12.21 (major), 11.34 (minor), 63:37 er;Yield: 50% (20 mg); [α]D25 = -3.8 
(c 0.71, CHCl3). 
3.8.3.15 (R)-4-(3-(Benzyloxy)phenyl)-5-nitropentan-2-one (4n) 
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Reaction was performed with 30 mg (0.11 mmol) of nitroolefin 3n, 86µL (1.17 mmol) of 
acetone and 36 µL of catalyst solution 1 or 1a following the general procedure. 
Viscous oil; IR (υmax): 2925, 1716, 1553, 1379, 1258, 756 cm-1;1H NMR (300 MHz, CDCl3) 
δ: 7.47-7.19 (m, 6H, ArH), 6.91-6.71 (m, 3H, ArH), 5.02 (s, 2H. –OCH2), 4.69-4.50 (m,2H), 
4.01-3.90 (m,1H, Ha), 2.86 (d, J = 7.0 Hz, 2H), 2.09 (s, 3H, -COCH3);13C NMR (125 MHz, 
CDCl3)δ: 205.9, 159.2, 140.5, 136.7, 130.1, 128.6, 128.1, 127.6, 119.9, 114.5, 113.8, 79.4, 
70.0, 46.1, 39.0, 30.4;HRMS (ESI): m/z calculated for [C18H19NNaO4] 336.1206 [M+Na]+, 
found 336.1234;HPLC: chiral pak-IC column, 210 nm, hexane/isopropanol = 75:15, 1.0 
mL/min, with catalyst 1 Rt = 19.04 (major), 20.23 (minor), 69:31 er; Yield: 53% (19 
mg);  [α]D25 = -9.07 (c 0.86, CHCl3); with catalyst 1a Rt = 19.09 (major), 20.30 (minor), 
67:33 er;Yield: 50% (18 mg);  [α]D25 = -7.06 (c 0.7, CHCl3). 
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4.1 Introduction 
Uncontrolled growth and spread of abnormal cells is generally termed as cancer.1  It is a 
leading health issue that at some point will directly or indirectly affect every person in their 
life time. More than 30% of the cancer patients diagnosed in Australia do not survive five 
years after diagnosis.2 In 2020 nearly 150,000 Australians are expected to be diagnosed.3 
The treatments currently employed for cancer include surgery, radiotherapy, 
chemotherapy, hormone therapy and immunotherapy.4 However, due to the enormous 
mortality rate of cancer, development of drug resistance in the cancer cells and unwanted 
effects of the drugs, there is urgent need to design and synthesis of new anti-cancer drugs. 
Dibenzodiazepine structural analogues, dibenzodiazepinones and dibenzooxazepines are 
most significant scaffolds in pharmacology. The heterocyclic skeleton of these compounds 
is one of the key structures which are widely utilized in many biologically important 
pharmaceutical agents. In particular the5H-dibenzo [b,e][1,4]diazepin-11(10H)-one is a 
significant scaffold due to the diverse therapeutic properties of its various derivatives. This 
scaffold 1 is found in many proven neuroleptic5 anti-allergic,6 anti-cancer and 
schizophrenic drugs. The dibenzodiazepinone core skeleton is also part of many 
pharmaceutical drugs that possess anti-inflammatory,7 antibiotic, anticonvulsant, sedative, 
hypnotic, and antidepressant properties.8 
Furthermore it also displays antimicrobial,9 antihypertensive10 properties and has 
applications in anti-HIV and as inhibitors of HIV protease11 agents. Pirenzapine 2, a tricyclic 
diazepinone derivative is a selective antimuscarinic agent used for the treatment of peptic 
ulcers. Despite its side effects, clozapine 3 (Figure 4.1)remains one of the most commonly 
effective antipsychotic agents available, and its utility for the  treatment of schizophrenia12 
disorders has spanned four decades. Olanzapine 4 is also an antipsychotic effective against 
Schizophrenia. Careful scrutiny of dibenzodiazepinones led to the discovery of drug leads 
such as Chk1 kinase inhibitors 5 (antagonist)13 and the histone deacetylase HDAC14 
inhibitor 7. Diazepinomicin 6 (Figure 4.2) is an unusual farnesylated-dibenzodiazepinone 
secondary metabolite that was recently isolated8a,15  from Micromonospora. Surprisingly, it 
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contains the dibenzodiazepinone skeleton that is unprecedented among natural products 
and its biosynthesis16 was also described recently. 
 
Figure 4.1The dibenzodiazepinone scaffold and some therapeutic dibenzodiazepines 
Compound 6 possesses (Figure 4.2) anti-tumor, anti-bacterial, and anti-inflammatory 
activity, 6 has also demonstrated in vivo activity in mouse models against breast, prostate, 
glioma tumours andinduced17 cytotoxicity in human hepatocellular carcinoma cell lines. In 
this way this core moiety and its derivatives established itself as an important molecule for 
investigation for various biological activities. 
 
 
Figure 4.2 Other dibenzodiazepinone therapeutic compounds 
Biological properties of 1,2,3-triazoles 
Many 1,2,3-triazole containing chemical entities were observed biologically active18 and 
some of them showed promising anti-fungal and anti-bacterial properties. Furthermore, 
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they were also proved as anti-cancer19 agents however, there are only few triazole 
containing molecules which entered clinical trials for example cephalosporin antibiotic 
cefatrizine, β-lactam antibiotic tazobactam(inhibits the action of bacterial β-lactamase) and 
calcium channel blocking anti-cancer compound carboxyamidotriazole (Figure 4.3). In 
addition, 1,2,3-triazoles also exhibited anti-tuberculosis20 (Figure 4.3) properties and acted 
as the inhibitors of HIV protease and HDAC.  
 
Figure 4.3 Some of biological-active 1,2,3-triazole compounds  
Due to the significance in medicinal chemistry and simple click chemistry used for the 
construction of 1,2,3-triazoles, many research groups synthesized and evaluated triazole 
analogues for anti-cancer21 and other biological activities. In addition, triazoles are capable 
of interacting with the biological targets through H-bonding22 and stable to metabolic 
degradation. Besides using triazole derivatives as organocatalysts23 for organic 
transformations, we also concentrated our investigation on new triazole derivatives for 
their biological activities. And hence, few dibezodiazepinone-triazole hybrid structural 
analogues were designed 45a-k (Scheme 4.16) with an expectation of good anti-cancer 
activity. We anticipated that, the combination of two pharmacophores dibenzodiazepinone 
and triazole may produce chemical entities with anti-cancer and/or other biological 
activity.  
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4.2 Previous synthetic approaches to dibenzodiazepinones 
The synthesis of 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 1 has been known 
since 1924.24  The diverse therapeutic application of dibenzodiazepinone derivatives and 
related compounds in medicinal chemistry has stimulated considerable synthesis interest 
in the construction of this tricyclic ring privileged scaffold. Many research groups have 
developed various synthetic strategies to construct the ring skeleton and derivatives. 
 
4.2.1 Giani’sone-step approach25 
In 1985 Giani and co-workers documented a single step synthesis of 5,10-dihydro-11H-
dibenzo[b,e][1,4]diazepin-11-one 10 (Scheme 4.1). In their approach, substituted or simple 
2-chlorobenzoic acids 8 and simple or substituted o-phenylenediamine 9 were refluxed in 
chlorobenzene with copper powder for 6-8 hours, to afford the corresponding  
 
 
 
dibenzodiazepines in 3- 40% yield. Interestingly, despite the reported low yield this one-
step method has been cited several times in the literature.    
 
4.2.2 Lu and Alper’s approach26 
The approach of Lu and Alper involves an intramolecular carbonylation reaction with silica 
based palladium-complexed dendrimers for the construction of heteroatom (oxygen, 
nitrogen and sulfur) containing heterocycles. This work mainly focussed on the synthesis of 
oxygen containing seven and eight membered heterocycles. However, the synthesis of 
nitrogen containing heterocycles such as dibenzodiazepines 12 and sulfur containing seven 
membered heterocycles are also discussed. This method employs substituted N-methyl-N-
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(2-iodophenyl)-1,2-benzenediamines 11, carbon monoxide gas (100 psi ) , DIPEA and 
dendrimer-Pd in toluene at 80 ᵒC. (Scheme 4.2) 
 
4.2.3 Bunce’s approach27 
In 2006, Bunce and Schammerhorn reported the reductive-lactamization reaction for the 
construction of dibenzodiazepines. The nitro group in compound 13 that originated from 
the coupling of 2-nitroaniline with 2-iodomethylbenzoate was reduced and cyclised 
(lactamised) in one pot using soluble Fe-AcOH catalyst at 115 ᵒC (Scheme 4.3). 
 
 
4.2.4 The Al-Tel et al.synthesis28 
Al-tel and co-workers documented the POCl3 mediated intramolecular aromatic 
substitution cyclization or lactamisation of ethyl-2-(phenylamino)phenylcarbamate 14 in 
to 1,4-dibenzodiazepinones 15 in fair yield 62%.(Scheme 4.4) The compound 14 was 
prepared in three steps. 
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4.2.5 The Garattini et al. method29 
The multistep synthesis of dibenzodiazepinone derivative 19 (Scheme 4.5) was reported 
by Garattini’s research group in 2010. First step, the cross-coupling or C-N bond formation 
reaction between anthranilic acid 16 and o-bromo nitro benzene 17, produced18. 
 
This step was known initially in first synthesis of the dibenzoazepines. The only change 
introduced in this step was the use of the solvent 1-pentanol. The later, reduction of the 
nitro group was performed with sodium dithionite in ethanol. Then amine 19 was intra-
molecularly coupled with the carboxyl group using EDCI, HOBt under standard amide 
coupling conditions to afford 20(Scheme 4.5).  
4.2.6 Buchwald’s approach30 
In 2011, Tsvelikhovsky and Buchwald published the Pd-catalyzed ligand assisted cross-
coupling and condensation cyclization reaction for the construction of various 
dibenzodiazepines and structural analogues (Scheme 4.6).  
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In this method, alkyl-2-(2-chlorophenylamino) benzoate 21 was cross-coupled with 
ammonia in presence of Pd2(dba)3 catalyst and ligand (L). 
4.2.7 Ma’s approach31 
Ma and co-workers in 2011 utilized the CuCl catalysed double amination of o-aromatic 
dibromides 22(Scheme 4.7) to furnish the core dibenzodiazepine structure23. 
 
 
 
4.2.8 Yi’s one step synthesis32 
The single step synthesis of dibenzodiazepinones was publishedby Yin and co-workers in 
2013. The reaction was performed in a pressure tube with ethyl-2-iodo-benzoate24, o-
phenylenediamine 25 and CuI as catalyst in presence of base Cs2CO3 (Scheme 4.8).  
Ethyleneglycol was used ensuring that the reaction temperature was maintained at 100 ᵒC. 
 
 
 
4.2.9 Zhao and Du’s Oxidative approach33 
In 2014, Zhao and co-workers documented the hypervalent reagent PhI(OAc)2(PIDA) 
mediated oxidative electrophilic cyclisation to efficiently form 1,4-dibenzodiazepine 
compound (27) (Scheme 4.9). The N-methoxy-2-(methylphenylamino)benzamide 26 was 
assembled in four steps using known aromatic cross-coupling reactions and the product 27 
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was obtained in moderate to good yields except for when R1 = 4-NO2 which produced the 
homocoupled  product from 27.  
 
 
4.2.10 Yao’s approach34 
Gawande et al. published a one pot Cu-catalyzed cascade C-N bond formation reaction for 
the synthesis of 1,4-benzodiazipinones 29 in 2014. In this method substituted 2-
iodo(halo)-N-substituted benzamides 27 were reacted with 2-iodoanilines 28 in the 
presence of CuI catalyst in DMSO at 135 ᵒC. This efficient one-pot protocol provided 
substituted dibenzodiazepine in good yields (Scheme 4.10). 
 
 
4.2.11 Shi’s enantioselective approach35 
Recently Wang et al. documented the first organocatalytic method to prepare the 
bicyclo[1,4]diazepine structure 36 (61-99% yield). They used chiral organophosphoric 
acids 30 (Scheme 4.11) as organocatalysts for the enanatioselective multicomponent 
reaction (OEMCR) whereby a 1,3-dicarbonyl compound 31, aldehyde 32 and o-
phenylenediamines 33 served as reaction components. 
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4.3 Results and Discussions 
Although, the methods discussed above have contributed to the construction of the 
diazepine skeleton, unfortunately, most of the methods require high reaction temperatures, 
transition metals and considerable purification of the products. So despite the quick one 
step assembly of most of these scaffolds, the synthesis of [1,4]-dibenzodiazepinones 
continues to be a challenging task. In view of the enormous medicinal applications and 
demand for this core ring/skeleton, the necessity for the development of more efficacious 
methodologies for the synthesis of dibenzodiazepinones is highly desirable. Besides 
making use of the existing methods for the synthesis of dibenzodiazepinone analogues, we 
also examined readily scalable and versatile novel approaches for the construction of 
analogues. 
4.3.1 Beckmann rearrangement (BKR) of N-methylacridone oxime 
Hidetsura Cho et al. reported36 the reductive ring expansion of acridone oxime 37 to 38 
with DIBAl-H (Scheme 4.12). Interestingly, there is no mention in the literature concerning 
the acridone oxime rearrangement to dibenzodiazepinone 1. 
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The conversion37 of xanthone oxime and thioxanthone oximes to oxazepinones and 
thiazepinones respectively is known. But the BKR of acridone oxime has not been reported.  
After careful scrutiny of literature on Beckmann rearrangement reaction (BKR)38 it was   
hypothesised that the BKR of acridone oximes could be a simple route to the  
dibenzodiazepene scaffold. All attempts to synthesise the oxime 39 from the ketone 
precursor 40 were unsuccessful. However, in 2 steps, using literature protocol39 N-
methylacridone oxime 39 was prepared from N-methyl acridone 40 (Scheme 4.13). Using 
the reagent diborane in THF, carbonyl functionality in 40 was reduced. The benzylic proton 
signal singlet at δ 3.81 in the 1H-NMR indicated the reduction of carbonyl group to 
methylene and also the signal at 33.2 ppm in 13C-NMR further confirmed structure 41. 
When 41 was treated with KHMDS and t-BuONO, after reaction work up, the oxime 39 was 
obtained40  in 91 % yield (Scheme 4.13).  
 
 
 
Figure 4.4 ORTEP diagram of oxime39 
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Disappearance of the benzylic protons and carbon signals in the NMR spectra confirmed 
the formation of oxime. In addition, single-crystal X-ray diffraction analysis data (Figure 
4.4) supported the formation of 39. Attempted BKR reaction of 39 by refluxing with PCl5 in 
CH3CN yielded the de-oximated N-methyl acridone starting material. Other reagents and 
reaction conditions investigated as shown in Table 4.1 were also fruitless. 
 
 
 
Table 4.1 Investigated conditions for BKR of 39 
Entry Reaction conditions Product 
1 PCl5, CH3CN, reflux, 5-10 h 40 
2 TsCl/ZnCl2(1:1), CH3CN, reflux, 5 h 40 
3 TsCl, CH3CN, reflux, 4-5 h No reaction 
 
Kuhara41and co-workers found that oxime tosylate esters can undergo BKR (Note they did 
not account for acid catalyzed BKR without ester-like precursors). Using the literature42 
procedure, 39 was converted to the tosyl derivative 42 in 85% yields as shown in Scheme 
4.15. Then, compound 42 was subjected to BKR by refluxing in pyridine for 4-5 h. All the 
attempted BKR conditions shown in(Table 4.2) did not lead to the desired rearranged 
product.  
 
 
Chapter IV 
 
 
83 | P a g e  
 
Table 4.2 
Entry Reaction conditions Product  
1 Py, reflux, 4-5 h 40 
2 MeOH, reflux, NR 
3 CH3COOH, MeOH, reflux, 40 
 
BKR42 of cyclohexanone oxime using TsCl afforded deoximated product that is 
cyclohexanone. However, increase of TsCl loading provided the rearranged product that is 
caprolactam in better yields. The same condition in our case did not give the desired 
rearranged product. 
4.3.2 Conclusion 
To date, our attempted methods to effect the BKR of N-methyl acridone into ring expanded 
lactam products to deliver the dibenzodiazepine scaffold has not been achieved. We 
assume that the aryl migration is not happening in the reaction because of the inactive 
aromatic rings. Finding effective BKR methods and conditions is a work in progress. 
4.4 Preparation of 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one analogues 
Dibenzodiazepinone-triazole analogues were prepared following depicted Scheme 4.16. 
Initially, ethyl-2-iodobenzoate 23 was allowed to react32 with o-phenylenediamine24 in 
presence of 10 mol% CuI in pressure tube at 100 ᵒC to obtain cyclised product 1 in 50% 
yield. Amide proton signal was observed at δ 8.63 (singlet) in 1H NMR and signal at 168.1 
ppm corresponding to amide carbonyl carbon in 13CNMR further confirmed the formation 
of product. Propargylation of 1 was first carried out with propargylbromide and NaH in 
anhydrous THF solvent at ice-bath temperature. But, these conditions did not afford the 
propargylated product 43(Scheme 4.16). 
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Then, reaction was carried out with n-BuLi at -20 ᵒC in freshly distilled dry THF solvent to 
yield desired N-propargylated compound 43 in 72% yield. Decreasing the temperature to -
78 ᵒC did not increase the yield. Formation of the product was evident from 1H NMR where 
amide proton signals disappeared and triplet (at δ 2.39), and doublet (at δ 4.68) belonging 
to propargyl group appeared.  The carbon signals of the propargyl group in 13C NMR at 
80.1, 72.0, and 40.3 ppm provided additional evidence for the insertion of the propargyl 
group in scaffold 43. Compound 43 was subjected to click reaction conditions to construct 
1,2,3-triazole ring. Different benzyl azides 44a-k were prepared from respective aldehydes 
following the procedure in literature43, these azides successfully underwent 3+2 
cycloaddition (CuAAC) with compound 43 in presence of pentahydrated CuSO4, and 
sodiumascorbate in tBuOH/H2O solvent to give triazole-products 45a-k (Scheme 4.16). 
Formation of triazole ring was determined by characteristic singlet in aromatic region in 
1H, by peak at around 120 ppm in 13C NMR, and by mass spectral analysis. 
4.5 Biology 
4.5.1 In vitro cytotoxic activity of 1, 43 and 45a-k  
All the synthesised dibenzodiazepinone-triazole derivatives were screened for their 
anticancer activity against five different human tumor cell lines including prostate (PC3), 
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lung (A549), brain (U87MG), and breast (MCF7 and MDAMB-231) using MTT assay and the 
results are illustrated in Table 4.3. The results from Table 1 indicated that most of the 
synthesised compounds (43, 45a, c-i) displayed moderate to potent growth inhibition 
against the tested cancer cells and selective potency against MDAMB-231 cells. Compounds 
45a, 45c-45d and 45f-45i displayed remarkable growth inhibition on MDAMB-231 cells 
which are superior to the standard 5-fluorouracil.  
Table 4.3 Anti-proliferative activities a(IC50-µM) of the 5,10-dihydro-11H-
dibenzo[b,e][1,4]diazepin-11-one and derivatives (1,43 and 45a-k ) 
Compound PC-3b A549c U87MGd MCF-7e MDAMB-231e 
1 41.89±2.7 37.10±1.3 8.97±0.9 >50 >50 
43 0.98±0.3 19.01±3.7 22.19±0.8 7.63±1.3 16.51±1.3 
45a 4.21±0.6 0.71±0.2 6.97±2.1 7.29±0.8 0.73±0.2 
45b >50 47.86±2.7 32.85±1.6 0.93±0.5 42.62±3.9 
45c 0.47±0.08 >50 39.39±1.9 0.65±0.1 1.52±0.3 
45d 17.28±1.1 26.68±0.4 37.72±0.6 >50 4.08±0.9 
45e 8.63±1.0 11.32±0.5 48.21±2.7 5.27±0.9 >50 
45f 7.21±0.8 8.37±1.0 2.06±0.5 4.12±0.09 3.53±0.1 
45g 1.12±1.2 4.97±0.9 24.32±1.4 39.01±0.8 2.31±0.5 
45h >50 8.78±1.11 1.78±1.3 10.26±0.8 0.43±0.8 
45i >50 13.30±0.5 31.21±1.0 7.48±0.7 3.50±0.6 
45j 10.67±1.2 10.70±1.0 13.48±0.6 17.78±0.5 10.19±0.8 
45k >50 >50 >50 29.61±1.3 >50 
5-FUf 1.44±0.3 3.47±0.9 3.61±0.5 nd nd 
 
a 50% inhibitory concentration and mean ± SD of three individual experiments performed in 
triplicate; bprostate cancer; clung cancer; dglioblastoma  and ebreast cancer cells; f5-fluoro uracil 
was included as reference standard; ndnot determined. 
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Moreover, 45a, 45c and 9f displayed significant broad spectrum growth inhibition against 
all the tested cancer cells with IC50 values in the range of 0.71-8.23 µM.  Further, 45c 
displayed selective potency growth inhibition of PC-3 (IC50-0.47 µM) and MCF-7 (IC50-0.65 
µM) cell lines which are superior to the standard drug 5-Flurouracil. Interestingly, N-
propargylated compound 43 that doesn’t contain triazole ring also exhibited considerable 
anti-tumour activity against PC-3 tumour cells (IC50- 0.98 µM) and breast cancer cells MCF-
7 (IC50-7.63 µM). Substituents at meta-position of the ring C seemed to have significant 
effect on activity for example, as both 3-NO2 (45c) and 3-F (45f) substituted compounds 
exhibited significant growth inhibition activities. However, the unsubstituted compound 
(45a) on the C ring also displayed substantial growth inhibition. On the other hand, para-
substituted compounds displayed mixed results. For instance, 4-fluoro (45d), 4-
trifluoromethoxy (45k), and 4-nitro (45b) substituted compounds are ineffective and 4-
chloro (45g) scaffold showed remarkable cytotoxic activity.  
4.5.2Colony formation inhibition essay 
Anti-proliferative activity of the most active compound in the series 45a was further 
confirmed by clonogenic cell survival assay on A549 and MDAMB-231 cells. This assay 
reflects the capability of a single cell to rise into a colony and it is also considered as the 
standard for determining long term cell viability because they reflect all modes of cell death 
or arrest.44 
 
Figure 4.5 Effect of compound 45a on the colony formation ability of A549 and MDA-MB-231 cells.  
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As shown in Figure 4.5 treatment of A549 and MDAMB-231 cells with 45a resulted in 
inhibition of colony formation in a dose dependent manner. The formation of colonies was 
completely inhibited by the compound 45a at 10 µM concentration in both the treated 
cells. This indicates the ability of 45a on dose dependent inhibition of colony formation 
ability and proliferation of A549 and MDAMB-231 cells. 
4.5.3 Invitro cell migration assay 
Migratory and invasive activities of tumor cells are the important characteristics of metastatic 
cancers.  Therefore, it was of interest to investigate the effect of compound 45a on tumor cell 
migration using wound healing assay45. Artificial wounds were created in the confluent monolayer 
A549 and MDAMB-231 cells using sterile 200 µL pipette tip and were treated with the different 
concentrations of compound 45a. Images were taken immediately (0 h) and 24 and 48 h after 
treatment. As depicted in Figure 4.6 treatment with 45a resulted in suppression of A549 and 
MDAMB-231 cell migration to the wounded area in a concentration dependent manner in 
comparison to the control. 
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Figure 4.6 Effect of compound 45a on A549 and MDAMB-231 cells migration in vitro.  A549 and 
MDAMB-231 cells were treated with 45a and artificial wounds were induced with 200 µL pipette. The 
edges of wound were captured immediately (0 h), 24and 48 h after respective treatments. Images 
were captured using a fluorescence microscope (Nikon). 
4.5.4 Cell cycle analysis 
 
Figure 4.7 Effect of compound 45a on A549 and MDAMB-231 cell cycle arrest. Cells were treated with 
45a and harvested after 24 h. The cells were fixed with ethanol, stained with propidium iodide and 
analyzed by BD-C6 accuri flow-cytometer. For each sample, 10,000 cells were used for sorting. 
Chapter IV 
 
 
89 | P a g e  
 
We next analysed the effect of compound 45a on cell cycle distribution using flow 
cytometry.  A549 and MDAMB-231 tumor cells were treated with different concentrations 
(0.5, 1 and 2 µM) of 45a for 48 h; cells were fixed in ethanol and stained with propidium 
iodide. Results presented in Figure 4.7 show that the proportion of A549 and MDAMB-231 
cells in G2/M phase gradually increased respectively from 31% (control) to 51% (2 µM) 
and 20% (control) to 63 % (2 µM). Similarly, the population in G0/G1 phase declined from 
49% to 34% and 73% to 33%, respectively after treatment with the compound. This 
indicates that 45a treatment resulted in the arrest of A549 and MDAMB-231 cells in G2/M 
phase of cell cycle.  
4.5.5 Apoptosis detection studies 
Apoptosis is a programmed cell death which plays an important role in the maintenance of 
tissue homeostasis and cell survival. Disruption or inappropriate regulation of apoptotic 
processes results in several diseases including cancer.46 Thus, inducing apoptosis in cancer 
cells has emerged as an attractive strategy in cancer therapy.47  
4.5.5.1 Hoechst staining 
Chromatin condensation, nuclear shrinking and DNA fragmentation are the typical 
characteristics of an apoptotic cell. Therefore, apoptosis inducing effect of compound 45a 
was investigated using the Hoechst staining (H 33242) assay. A549 and MDAMB-231 cells 
treated with different concentrations of 45a for 48 h were stained with Hoechst. As evident 
from Figure 4.8, control A549 and MDAMB-231 cells treated with DMSO showed uniformly 
dispersed chromatin, whereas compound 45a treated cells displayed typical apoptotic 
characteristics such as condensation of nuclei (arrowheads indicates apoptotic nuclei). 
These finding demonstrates that 45a could induce apoptosis in A549 and MDAMB-231 
cells. 
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Figure 4.8 Compound45a induced nuclear morphological changes of A549 and MDA-MB-231 cells. 
Images were captured by a fluorescence microscope (Nikon). 
4.5.5.2 Effect of compound 45a on mitochondrial membrane potential (ΔΨm) 
Mitochondrial membrane potential regulates the mitochondrial permeability and plays an 
important role in triggering apoptosis.48 In order to further investigate the apoptosis-
inducing effect of compound 45a, changes in the mitochondrial membrane potential were 
measured using Rhodamine 123 staining. Mitochondria with the intact ΔΨm can hold the 
Rh-123 probe and exhibits strong green fluorescence. Loss of ΔΨm results in decrease in 
green fluorescence due to the lack of Rhodamine-123 retention.49 A549 and MDAMB-231 
cells were treated with 45a for 48 h, and then stained with Rhodamine-123. The results 
from Figure 4.9 indicated that, treatment of 45a induced 20-35% decrease in ΔΨm in 
MDAMB-231 cancer cells and 15-30% in A549 cells in concentration dependant manner in 
compared to respective control cells, which indicates that 45a induces apoptosis in A549 
and MDAMB-231 cells through change in ΔΨm. 
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Figure 4.9 Compound 45a induced loss of mitochondrial membrane potential (ΔΨm) in A549 and 
MDA-MB-231 cells analysed using Rhodamine 123 staining. The loss in intensity of fluorescence was 
measured by spetrofluorometer. Data are mean ± SD from three independent experiments. 
 
4.5.5.3 Measurement of reactive oxygen species (ROS) levels 
Decline in mitochondrial membrane potential (ΔΨm) and increase in the level of 
intracellular ROS are closely related in the course of apoptosis. Moreover, generation of 
ROS is considered as one of the key mediators of apoptotic signalling and many if not most 
of the anti-tumour agents exhibit their cytotoxic effects through the generation of ROS.50,51 
Thus to investigate whether ROS accumulation was involved in compound 45a induced 
apoptosis, A549 and MDAMB-231 cells were treated with different concentrations of 
compound 45a for 48 h and incubated with carboxy-DCFDA to inspect 45a mediated 
production of ROS. As shown in Figure 4.10 there is a gradual increase in green carboxy-
DCF fluorescence (correlates with ROS concentration) with increasing the concentration of 
compound 45a treated A549 and MDAMB-231 cells and it is more prominent with 
MDAMB-231 cells. These results clearly indicate that 45a could induce the ROS generation.  
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Figure 4.10 Effect of compound 45a on the intracellular levels of ROS. A549 and MDAMB-231 cells 
were treated with different concentrations of 45a (0.5, 1 and 2 µM)for 48 h and stained with carboxy-
DCFDA. Images were captured by a fluorescence microscope (Nikon). 
4.6 Conclusion 
In this chapter, methods to find a transition metal free and scalable synthesis of the 
dibenzodiazepinone scaffold were investigated. The attempted Beckmann rearrangement 
of the acridone oxime 36 by employing various reaction conditions did not provide the 
desired ring expanded amide product 36a. In an effort to discover novel anti-cancer agents, 
a series (45a-k) of dibenzodiazipinone-triazole derivatives were prepared, characterized 
and evaluated against five human tumour cell lines. All the synthesized compounds 
exhibited moderate to good activity against five cancer cell lines. In particular, compound 
45a exhibited potent in vitro anti-cancer activity among the tested compounds with the 
IC50 values in the range of 0.71 to 7.29 µM. It is evident from the cell migration and 
clonogenic experiments that, migration and colony formation of the A549 and MDAMB-231 
cells was significantly affected by compound 45a. Flow cytometry analysis revealed that 
45a arrested both these cells in G2/M phase. Further apoptosis studies conducted on A549 
and MDAMB-231 cells revealed that compound 45a effectively induces apoptosis through 
drop in mitochondrial membrane potential (ΔΨm) and increases the ROS generation in 
A549 and MDAMB-231. Overall, these results suggest that compound 45a has the potential 
Chapter IV 
 
 
93 | P a g e  
 
to be developed as lead and their further structural modification may produce promising 
anticancer agents. 
4.7 Experimental section 
4.7.1 Chemistry 
4.7.1.1 10-Methyl-9,10-dihydroacridine (41) 
 
To N-methylacridone (0.32 g, 1.53 mmol) in a two neck round bottom flask equipped reflux 
condenser under nitrogen atmosphere was added dry THF (3 mL). To the suspension was 
added 2.1 mL of 1M BH3 in THF at room temperature and refluxed overnight.  THF was 
removed from the reaction mixture in rotary evaporator and partitioned between H2O (10 
mL) and EtOAc 15 mL. The organic layer was separated, washed with saturated brine 
solution, dried over anhydrous Na2SO4, and concentrated in vacuo giving a white solid in 
90% yield (0.27 g). This compound was used without further purification in the next 
reaction. 
1H NMR (300 MHz, CDCl3):δ 7.20 – 7.03 (m, 4H, ArH), 6.91 – 6.76 (m, 4H, ArH), 3.81 (s, 2H, 
Benzylic-CH2-), 3.30 (s, 3H, N-CH3); 13C NMR (75 MHz, CDCl3):δ 143.7, 127.5, 126.8, 124.3, 
120.5, 111.8, 33.2, 33.1; HRMS (ESI) m/z calculated for [M]+ [C14H13N] 195.1048, found 
195.1026. 
4.7.1.2 10-Methylacridin-9(10H)-one oxime (39) 
 
A two-necked 30-mL round-bottomed flask equipped with a magnetic stirring bar was 
charged with 10-methyl-9,10-dihydroacridine 41(0.24 g, 1.23 mmol) and anhydrous THF 
(3.6 mL). To the solution was added t-BuONO (176 μL, 1.48 mmol) at 0°C, followed by 
KHMDS (1M in toluene, 1.48 mL, 1.48 mmol) dropwise at 0°C. After 0.5 h, the reaction was 
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quenched with saturated aqueous NH4Cl, and the aqueous layer was extracted three times 
with ether. The combined organic extracts were washed with brine, dried over anhydrous 
sodium sulfate, and filtered. The organic solvents were removed under reduced pressure to 
leave the residue, which was purified by flash silica gel column chromatography (hexanes–
EtOAc= 4:1) to afford oxime 36 in 91% (0.25 g). 
1H NMR (300 MHz, CDCl3):δ 8.76 (dd, J = 8.1, 1.5 Hz, 1H, ArH), 7.87 (dd, J = 7.8, 1.5 Hz, 1H, 
ArH), 7.44-7.29 (m, 2H, ArH), 7.12-6.91 (m, 4H, ArH), 3.49 (s, 3H, N-CH3).;13C NMR (75 MHz, 
CDCl3): δ 145.6, 142.3, 140.7, 131.2, 130.8, 129.8, 124.7, 121.2, 120.6, 119.6, 116.7, 113.4, 
113.14, 34.0.;HRMS (ESI) m/z calculated for [M+H]+ [C14H13N2O] 225.1028, found 
225.1014. 
4.7.1.3 10-Methylacridin-9(10H)-one O-tosyl oxime (42) 
 
To the oxime (52 mg, 0.23 mmol) in an rb flask with magnetic stir bar, was added pyridine 
(1 mL) and reaction mixture was brought to -20 ᵒC. To this, tosyl chloride (52 mg, 0.27 
mmol) was added portion wise and stirred at the same temperature for 2-3 h. After 
completion of the starting material sat. CuSO4 solution (5 mL) was added and extracted into 
Et2O. Combined organic layers washed with brine, dried over anhydrous Na2SO4 and 
solvent was evaporated. Crude product was purified through flash column 
chromatography.  
Yield 85% (74 mg); 1H NMR (300 MHz, CDCl3):δ 8.55 (dd, J = 8.3, 1.5 Hz, 1H, ArH), 7.96 – 
7.85 (m, 3H, ArH), 7.53 – 7.36 (m, 2H, ArH), 7.26 (d, J = 8.3 Hz, 2H, ArH), 7.22 – 6.98 (m, 4H, 
ArH), 3.54 (s, 3H, N-CH3), 2.35 (s, 3H, Ph-CH3);13C NMR (75 MHz, CDCl3):δ 151.0, 144.7, 
141.9, 140.3, 132.9, 132.2, 131.4, 131.2, 129.4, 129.0, 125.7, 121.4, 120.4, 117.7, 114.6, 
114.0, 113.4, 34.31, 21.70.; HRMS (ESI) m/z calculated for [M+H]+ [C21H19N2O3S] 379.1116, 
found 379.1136. 
4.7.1.4 10-Dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one (1) 
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To a dried pressure tube was added o-phenylenediamine (0.3 g, 2.7 mmol), ethyl-2-
iodobenzoate (1.5 g, 5.5 mmol) under nitrogen followed by ethyleneglycol (6 mL), 10 mol 
% CuI (52 mg, 0.27 mmol) and K3PO4 tribasic (1.17 g, 5.5 mmol). Pressure tube was closed 
tightly and heated at 100 ᵒC for 4 h. After completion of the reaction (monitored by TLC) 
reaction mixture was cooled to room temperature and filtered over a pad of silica with 
CH2Cl2 to remove CuI and base residues. Then solvent was removed on rotary evaporator 
and the residue was purified on silica column chromatography using 25-30% EtOAc in 
hexane as solvent to give 1.  
Yield 50% (0.29 g); mp: 251-253 ᵒC; IR (υmax):3320, 3025, 1603, 1579, 1471, 1394, 1157, 
748 cm-1;  1H NMR (300 MHz, DMSO-d6): δ 8.63 (s, 1H, Amide NH), 6.60 (s, 1H, AmineNH), 
6.46 (dd, J = 7.9, 1.4 Hz, 1H, ArH), 6.19 – 6.08 (m, 1H, ArH), 5.87 – 5.63 (m, 6H, ArH);13C 
NMR (75 MHz, DMSO): δ 168.1, 150.4, 140.0, 133.2, 131.9, 129.6, 124.6, 123.0, 122.7, 121.2, 
120.9, 119.8, 119.0 ;HRMS (ESI) m/z calculated for [M+H]+ [C13H11N2O] 211.0866, found 
211.0860. 
4.7.1.5 10-(Prop-2-yn-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one (43) 
 
In a two neck round bottom flask compound 1(0.1 g, 0.47 mmol) was dissolved in freshly 
distilled dry THF (5 mL), under inert conditions. To that was added 1.5 mL of 1.6 M n-BuLi 
(5 equiv) at -20 ᵒC. After 5 min 80% propargylbromide in toluene (0.054 mL, 0.52 mmol) 
was added to the reaction and the mixture stirred for 1 h at the same temperature. 
Reaction was monitored by TLC after consumption of the starting material reaction was 
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quenched with saturated NH4Cl solution and partitioned between H2O and EtOAc. Organic 
layers were separated, combined, dried over anhydrous NaSO4 and concentrated on rotary 
evaporator below 46 ᵒC. Product was purified on silica column chromatography to yield 
propargylated scaffold 43.  
Yield: 72 % (80 mg); mp: 165-170 ᵒC ; IR (υmax): 3321, 3292, 2923, 1623, 1546, 1454, 1160 
cm-1; 1H NMR (300 MHz, CDCl3): δ 7.94 (dd, J = 7.8, 1.3 Hz, 1H, ArH), 7.72 – 7.57 (m, 1H, 
ArH), 7.39 – 7.25 (m, 1H, ArH), 7.20 – 6.90 (m, 4H, ArH), 6.83 (d, J = 8.0 Hz, 1H, ArH), 5.53 
(s, 1H, NH), 4.68 (d, J = 2.4 Hz, 2H, propargylic-CH2), 2.39 (t, J = 2.4 Hz, 1H, triple bond H); 
13C NMR (75 MHz, CDCl3): δ 168.1, 150.6, 143.1, 134.3, 133.1, 132.8, 126.2, 124.4, 124.2, 
122.9, 122.6, 120.3, 118.6, 80.1, 72.0, 40.3 ; HRMS (ESI): m/z calculated for [M+H]+ 
[C16H13N2O] is 249.1022 found 249.1015  
4.7.1.6 General procedure for the click reaction 
To the propargylated compound 43(50 mg, 0.20 mmol) and azide 44a-k (0.60 mmol) in 3 
mL of 1:1 t-BuOH/H2O was added 100 µL saturated CuSO4·5H2Osolution followed by 
catalytic amount of Na-ascorbate at ambient temperature. Reaction was allowed to stir for 
5-6 h, solvent was removed and product was extracted with CH2Cl2. Dichloromethane layer 
was dried over anhydrous sodium sulphate, solvent was evaporated in vacuo and residue 
was purified using silica column chromatography to obtain 45a-k.   
4.7.1.7 10-((1-Benzyl-1H-1,2,3-triazol-4-yl)methyl)-5,10-dihydro-11H-
dibenzo[b,e][1,4]diazepin-11-one (45a) 
 
Yield: 82% (50 mg); mp: 128-133 ᵒC; IR (υmax): 3301, 3069, 2936, 2123, 1631, 1480, 1320, 
1160, 765 cm-1;1H NMR (300 MHz, CDCl3) δ:  7.77 – 7.65 (m, 2H), 7.61 (dd, J = 7.5, 1.6 Hz, 
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1H, ArH), 7.35 – 7.10 (m, 7H, ArH), 7.05 – 6.85 (m, 3H, ArH), 6.80 (dd, J = 7.4, 3.8 Hz, 1H, 
ArH), 6.71 (d, J = 7.9 Hz, 1H, ArH), 5.42 (s, 3H, benzyl- CH2&-NH), 5.13 (d, J = 12.5 Hz, 2H, 
triazole-CH2); 13C NMR (75 MHz, CDCl3)δ:168.6, 150.8, 143.4, 134.7, 134.7, 132.6, 129.0, 
128.6, 127.9, 126.1, 125.0, 124.6, 124.2, 122.6, 120.2, 118.6, 54.1, 47.1; HRMS (ESI): m/z 
calculated for [M+H]+ [C23H20N5O] 382.1662 found 382.1663. 
4.7.1.8 10-((1-(4-Nitrobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-5,10-dihydro-11H-
dibenzo[b,e][1,4]diazepin-11-one (45b) 
 
Yield: 61% (31 mg); mp: 159-164 οC; IR (υmax): 3132, 3075, 1628, 1522, 1474, 1344, 1049, 
767 cm-1 ;1H NMR (300 MHz, CDCl3) δ: 8.13 (d, J = 8.7 Hz, 2H, ArH ), 7.79 (s, 1H, triazole H), 
7.68 (d, J = 8.1 Hz, 1H, ArH), 7.60 (d, J= 7.6 Hz, 1H)7.32-7.16 (m, 3H, ArH), 7.06-6.88 (m, 3H, 
ArH), 6.81 (d, J = 7.5 Hz, 1H, ArH), 6.72 (d, J = 8.0 Hz, 1H, ArH), 5.54 (s, 2H, benzylic-CH2), 
5.33 (brs, 1H, -NH), 5.13 (s, 2H, triazole-CH2); 13C NMR (75 MHz, CDCl3) δ: 168.7, 150.7, 
148.0, 145.9, 143.3, 141.7, 134.7, 132.7, 132.5, 128.5, 126.2, 124.9, 124.8, 124.7, 124.2, 
124.1, 122.7, 120.2, 118.6, 53.0, 47.1; HRMS (ESI): m/z calculated for [M+H]+ [C23H19N6O3] 
427.1513, found 427.1504 . 
4.7.1.9 10-((1-(3-Nitrobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-5,10-dihydro-11H-
dibenzo[b,e][1,4]diazepin-11-one (45c) 
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Yield: 68 % (35 mg); mp: 124-130 οC; IR (υmax): 3314, 3012, 2102,  1634, 1528, 1477, 1350, 
758 cm-1;1H NMR (300 MHz, CDCl3) δ:8.26-8.17 (m, 1H), 8.14 (s, 1H), 7.89 (s, 1H), 7.80 (dd, 
J = 12.2, 8.2 Hz, 1H, ArH), 7.67 (d, J = 8.8 Hz, 1H, ArH), 7.62 – 7.52 (m, 2H, ArH), 7.31 (m, 1H, 
ArH), 7.14-6.86 (m, 4H, ArH), 6.81 (d, J = 7.9 Hz, 1H, ArH), 5.63 (s, 2H, benzylic-CH2), 5.45 
(s, 1H, -NH), 5.24 (s, 2H, triazole-CH2); 13C NMR (75 MHz, CDCl3) δ:168.7, 150.7, 143.4, 
136.8, 134.6, 133.8, 132.7, 132.5, 130.2, 126.2, 124.9, 124.7, 124.1, 123.6, 122.8, 122.7, 
120.3, 118.6, 53.1, 47.0; HRMS (ESI): m/z calculated for [M+H]+ [C23H19N6O3] 427.1513, 
found 427.1503. 
4.7.1.10 10-((1-(4-Fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-5,10-dihydro-11H-
dibenzo[b,e][1,4]diazepin-11-one (45d) 
 
Yield: 70% (43 mg); mp: 109-114 οC; IR (υmax): 3305, 3129, 3069, 1628, 1513, 1474, 1154, 
764 cm-1; 1H NMR (300 MHz, CDCl3) δ: 7.70 (s, 1H, triazole H), 7.68 (dd, J = 1.6, 7.8  Hz, 1H, 
ArH), 7.62 ( dd, J = 1.8, 7.8  Hz, 1H, ArH), 7.25-7.12 (m, 3H, ArH), 7.05-6.89 (m, 5H, ArH), 
6.80 (dd, J = 1.9, 7.4  Hz, 1H, ArH), 6.72 (d, J = 7.9 Hz, 1H, ArH) 5.40 (s, 2H, benzylic-CH2), 
5.31 (brs, 1H, NH), 5.10 (s, 2H, triazole-CH2); 13C NMR (75 MHz, CDCl3) δ: 168.6, 150.7, 
145.6, 143.3, 134.7, 132.6, 132.6, 130.6, 130.5, 129.9, 129.8, 126.1, 124.9, 124.7, 124.4, 
124.2, 122.7, 120.1, 118.5, 116.2, 115.9, 53.3, 47.1; 19F NMR (300 MHz, CDCl3) δ:-112.7-
112.9 (m); HRMS (ESI): m/z calculated for [M+H]+ [C23H19FN5O] 400.1568 found 400.1567. 
4.7.1.11 10-((1-(2-Fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-5,10-dihydro-11H-
dibenzo[b,e][1,4]diazepin-11-one (45e) 
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Yield: 73 % (35 mg); mp: 168-173 ᵒC.; IR (υmax): 3326, 3151, 3057, 1613, 1486, 1226, 1042, 
758 cm-1; 1H NMR (300 MHz, CDCl3) δ:7.87 (s, 1H, triazole H), 7.80 (dd, J = 7.8, 1.3 Hz, 1H, 
ArH), 7.70 (dd, J = 7.4, 1.6 Hz, 1H, ArH), 7.46-6.97 (m, 8H, ArH), 6.90 (d, J = 7.3 Hz, 1H, ArH), 
6.82 (d, J = 7.9 Hz, 1H, ArH), 5.59 (s, 2H, benzylic-CH2), 5.45 (s, 1H, -NH), 5.22 (s, 2H, 
triazole-CH2); 13C NMR (75 MHz, CDCl3) δ: 168.6, 162.1, 158.8, 150.7, 143.3, 134.7, 132.6 
(split), 130.8 (split), 130.7, 130.3, 126.1, 125.0, 124.7, 124.2 (split), 122.7, 122.0, 121.9, 
120.2, 118.5, 115.9 115.6, 47.6 (split), 47.1; 19F NMR (300 MHz, CDCl3) δ -117.8-118.0 (m); 
HRMS (ESI): m/z calculated for [M+H]+ [C23H19FN5O] 400.1568 found 400.1563. 
4.7.1.12 10-((1-(3-Fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-5,10-dihydro-11H-
dibenzo[b,e][1,4]diazepin-11-one (45f) 
 
Yield: 70% (33 mg); mp: 143-148 ºC ;IR (υmax): 3312, 3051, 1622, 1471, 1120, 766 cm-1; 1H 
NMR (300 MHz, CDCl3) δ:7.73 (s, 1H, triazole H), 7.69 (dd, J = 7.8, 1.4 Hz, 1H, ArH), 7.60 (dd, 
J = 7.6, 1.7 Hz, 1H, ArH), 7.31-7.15 (m, 3H, ArH), 7.07-6.87 (m, 6H, ArH), 6.81 (dd, J = 12.6, 
5.3 Hz, 2H, ArH), 6.72 (d, J = 7.9 Hz, 1H, ArH), 5.42 (s, 2H), 5.14 (s, 2H, triazole-CH2); 13C 
NMR (75 MHz, CDCl3) δ:168.6, 164.6, 161.3, 150.7, 143.4, 137.0, 134.6, 132.6, 130.7, 130.6, 
126.2, 124.9, 124.7, 124.2, 123.5, 122.7, 120.2, 118.6, 115.8, 115.5, 115.0, 114.7, 53.5, 47.0; 
19F NMR (300 MHz, CDCl3) δ:-111.6(td, J= 8.9, 5.9 Hz); HRMS (ESI): m/z calculated for 
[M+H]+ [C23H19FN5O] 400.1568 found 400.1569. 
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4.7.1.13 10-((1-(4-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-5,10-dihydro-11H-
dibenzo[b,e][1,4]diazepin-11-one (45g) 
 
Yield: 75% (50 mg); mp: 135-140 ᵒC; IR (υmax): 3307, 3135, 1624, 1479, 1395, 1157, 1052, 
766 cm-1; 1H NMR (300 MHz, CDCl3) δ: 7.71 (s, 1H, triazole H), 7.68 (dd, J = 1.7, 8.0 Hz, 1H, 
ArH), 7.60 (dd, J = 2.0, 7.4  Hz, 1H, ArH), 7.28-7.16 (m, 4H, ArH), 7.12-7.06 (m, 2H, ArH), 
7.04-6.88 (m, 3H, ArH), 6.79 (dd, J = 1.8, 7.1 Hz, 1H, ArH), 6.71 (d, J = 7.9 Hz, 1H, ArH) 5.39 
(s, 2H, benzylic-CH2), 5.34 (brs, 1H, NH), 5.11 (s, 2H, triazole-CH2); 13C NMR (75 MHz, 
CDCl3) δ: 168.6, 150.7, 145.6, 143.3, 134.7, 134.6, 133.2, 132.6, 132.6, 129.3, 129.2, 126.1, 
124.9, 124.7, 124.5, 124.1, 122.7, 120.2, 118.5, 53.6, 47.2; HRMS (ESI): m/z calculated for 
[M+H]+ [C23H19ClN5O] 416.1273, found 416.1236. 
4.7.1.13 10-((1-(3,4,5-Trimethoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)-5,10-
dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one (45h) 
 
Yield: 90% (80 mg); mp: 182-188 ᵒC; IR (υmax): 3311, 3132, 3946, 1631, 1504, 1462, 1238, 
1126, 761 cm-1; 1H NMR (300 MHz, CDCl3) δ: 7.76 (s, 1H, triazole H ), 7.68 (dd, J = 7.8, 1.4 
Hz, 1H, ArH), 7.61 (dd, J = 7.5, 1.7 Hz, 1H, ArH), 7.27-7.17 (m, 2H, ArH), 7.06-6.89 (m, 3H, 
ArH), 6.85-6.76 (m, 1H, ArH), 6.73 (d, J = 7.9 Hz, 1H, ArH), 6.41 (s, 2H, ArH), 5.36 (s, 2H, 
benzylic-CH2), 5.14 (s, 2H, triazole-CH2), 3.79 – 3.72 (m, 9H, -OCH3); 13C NMR (75 MHz, 
CDCl3) δ: 168.6, 153.6, 150.7, 143.3, 138.2, 134.7, 132.7, 132.5, 130.1, 126.2, 124.9, 124.7, 
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124.6, 124.1, 122.7, 120.2, 118.6, 105.2, 60.8, 56.2, 54.5, 47.1; HRMS (ESI): m/z calculated 
for [M+H]+ [C26H26O4N5] 472.1979 found 472.1961. 
4.7.1.14 10-((1-(2,5-Dimethoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)-5,10-dihydro-
11H-dibenzo[b,e][1,4]diazepin-11-one (45i) 
 
Yield: 68% (50 mg); mp: 171-175 ᵒC; IR (υmax): 3259, 3220, 2948, 1640, 1504, 1226, 1036, 
770 cm-1; 1H NMR (300 MHz, CDCl3) δ: 7.84 (s, 1H, triazole H), 7.76 (ddd, J = 1.6, 7.7, 13.9 
Hz, 2H, ArH), 7.34-7.27 (m, 1H, ArH), 7.14-6.97 (m, 3H, ArH), 6.92-6.83 (m, 3H, ArH), 6.80 
(d, J= 7.9 Hz, 1H, ArH), 6.72 (d, J = 7.6 Hz, 1H, ArH), 6.75-6.71 (m, 1H, ArH), 5.51 (s, 2H, 
benzylic-CH2), 5.37 (brs, 1H, NH), 5.20 (s, 2H, triazole-CH2), 3.83 (s, 3H,-OCH3), 3.74 (s, 3H, -
OCH3); 13C NMR (75 MHz, CDCl3) δ: 168.5, 153.6, 151.2, 150.7, 144.9, 143.3, 134.8, 132.6, 
132.5, 126.0, 125.1, 124.8, 124.7, 124.3, 124.0, 122.6, 120.1, 118.5, 115.8, 114.7, 111.7, 
55.9, 55.7, 49.0, 47.1; HRMS (ESI): m/z calculated for [M+H]+ [C25H24O3N5] 442.1874 found 
442.1876. 
4.7.1.15 10-((1-(Benzo[d][1,3]dioxol-4-ylmethyl)-1H-1,2,3-triazol-4-yl)methyl)-5,10-
dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one (45j) 
 
Yield: 80% (41 mg); mp: 118-123 ᵒC;IR (υmax): 3328, 2922, 1670, 1451, 1035, 772 cm-1; 1H 
NMR (300 MHz, CDCl3) δ:7.86-7.75 (m, 2H, ArH & triazole-H), 7.71 (d, J = 7.5 Hz, 1H, ArH), 
7.36-7.24 (m, 1H, ArH), 7.17- 6.97 (m, 3H, ArH), 6.94-6.70 (m, 5H, ArH), 5.99 (s, 2H, -O-CH2-
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O-), 5.42 (s, 2H, benzylic-CH2), 5.38 (brs, 1H, -NH), 5.20 (s, 2H, triazole-CH2); 13C NMR (75 
MHz, CDCl3) δ: 168.6, 150.7, 148.2, 147.9, 145.4, 143.3, 134.7, 132.6, 132.6, 128.3, 126.1, 
125.0, 124.7, 124.2, 122.7, 121.9, 120.1, 118.5, 108.5, 108.5, 101.3, 54.0, 47.1; HRMS (ESI): 
m/z calculated for [M+H]+ [C24H20O3N5] 426.1566 found 426.1563. 
4.7.1.16 10-((1-(2-(Trifluoromethoxy)benzyl)-1H-1,2,3-triazol-4-yl)methyl)-5,10-
dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one (45k) 
 
Yield: 80% (45 mg); mp:130-135 ᵒC; IR (υmax): 3305, 2927, 2958, 1628, 1477, 1253, 1048, 
761 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.76 (s, 1H, triazole-H), 7.71 (dd, J = 7.8, 1.4 Hz, 1H, 
ArH), 7.66-7.56 (m, 1H, ArH), 7.33 (m, 1H, ArH), 7.29-7.16 (m, 4H), 7.13-6.90 (m, 4H, ArH), 
6.85-6.77 (m, 1H, ArH), 6.72 (d, J = 7.9 Hz, 1H, ArH), 5.55 (s, 2H, benzylic-CH2), 5.28 (s, 1H, -
NH), 5.15 (s, 2H, triazole-CH2);13C NMR (75 MHz, CDCl3) δ:168.5, 150.6, 146.8, 143.3, 134.7, 
132.6, 130.2, 130.1, 127.4, 126.1, 125.0, 124.7, 124.2, 122.7, 120.5, 120.1, 118.5, 48.4, 47.0; 
19F NMR (300 MHz, CDCl3) δ -57.21 (d, J = 1.5 Hz).; HRMS (ESI): m/z calculated for [M+H]+ 
[C24H19F3 N5O2] 466.1491 found 466.1504. 
4.7.2 Biology 
4.7.2.1 Cell culture 
PC-3, A549, U87MG, MCF-7 and MDAMB-231 cells were purchased from ATCC (Manassas, 
VA). The PC-3, A549 and MDAMB-231 cells were grown in RPMI 1640 medium (GIBCO-
Invitrogen, NY) with 10% fetal bovine serum (FBS) and supplemented with penicillin G 
(100 µg/mL), glutamine (2 mmol/L), and streptomycin (100 µg/mL) at 37 ᵒC under 5% 
CO2. U87MG and MCF-7 cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 10% fetal bovine serum (FBS), 1% penicillin/ streptomycin at 37 ᵒC 
under 5% CO2. The medium was changed every two days. After reaching 80-90% 
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confluence, cells were treated with 0.25% trypsin-EDTA for further passage.  For all the 
experiments cells were used at passages 4-10. 
4.7.2.2 MTT assay 
MTT cell proliferation assay was conducted on PC-3, A549, U87MG, MCF-7 and MDAMB-
231 cancer cell lines to test the compounds 45a-k, 1 and 43. Cells were seeded at a density 
of 3000-5000 cells per well in a 96 well plate depending on the doubling time. Seeded 
plates were allowed for 24 h at 37 ᵒC and 5% CO2 in incubator. After 24 h, the culture 
media was removed, 100 µL of test compounds dissolved in DMSO and culture media was 
added to the cells in each well. Wells in which test compound was not added (containing 
only culture medium and DMSO) were used as the control. Then, the compound treated 
cells were incubated for 72 h maintaining the same conditions. 72 h later, culture medium 
was removed and 100 µL of MTT (Thiazoyl blue tertrazolium bromide) solution (5 mg/mL 
in culture media) was added to each well including control wells and further incubated for 
4 h. When the purple precipitate was visible in wells, media containing MTT was aspirated 
from the wells and to each well 100 µL of DMSO was added to dissolve the Formazan 
product. Plate covers were removed and absorbance in each well was measured in 
microtiter plate reader at 570 nm and a reference wavelength of 630 nm. The absorbance 
readings at 630 nm were subtracted from the 570 nm readings and the results were 
adjusted by dividing the average by the DMSO control to adjust for any toxicity that may 
have occurred in this control treatment set. The percentage inhibition was calculated as 
100-[(Mean OD of treated cell ×100)/Mean OD of vehicle treated cells (DMSO)]. The IC50 
Values were calculated using probit software. All the tests w ere repeated in at least three 
independent experiments. 
4.7.2.3 Colony formation inhibition assay 
 A549 and MDAMB-231 cells at the exponential phase were plated at a single cell density 
(500 cells/well) in two separate 6 well plates and allowed to adhere for 24 h in the 
incubator. Then, cells were incubated with culture medium containing compound 45a in 
10, 1 and 0.1 µM concentrations.  After 24 h, the medium was replaced with fresh culture 
medium and cells were incubated for further 14 days. The cells were washed with PBS, 
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fixed with 4 % paraformaldehyde and stained with 0.5% methylene blue in PBS for 30 min. 
Then, excess dye was rinsed off with distilled water several times. Plates were 
photographed with a digital camera. 
4.7.2.4 Cell cycle analysis 
A549 and MDAMB-231 cells were seeded in 6 well plates at a density of 1x106 cells/well 
and after 24 h, cells were treated with compound 45a in three different concentrations 0.5, 
1 and 2 µM. Cells treated with DMSO were used as control. 48 h after treatment, both 
floating and trypsinised cells were harvested and washed with PBS. Cells were fixed with 
70% ethanol for 30 mins at 4 ᵒC. Then, cells were centrifuged (1200 rpm for 5 min), the 
supernatant was discarded and the pellet was washed with PBS and stained the cells with 
propidium iodide staining buffer (PI (200 µg), 0.1% (v/v) Triton X-100, 2 mg DNAse-free 
RNAse A (Sigma) in 10 mL PBS)) for 15 min at ambient temperature in absence of light. 
Later, samples were analysed for propidium iodide-DNA fluorescence from 10000 events 
by flow cytometry using BD-C6 accuri flow cytometer. 
4.7.2.5 In vitro Migration Assay 
The wound healing assay has been used to examine the cell migration. In two separate 6 
well plates A549 cells and MDAMB-231 cells (5×105 cells per well) were cultured as 
confluent monolayers for 24 h. Then, using 200 µL sterile pipette tip the monolayers were 
gently scraped one time in the middle from one end to the other end to create a denuded 
zone of constant width. The wounded mono layers were twice washed with phosphate 
saline buffer (PBS) to remove non-adherent cells. Then, cells were treated with compound 
45a in different concentrations (0.5, 1 and 2 µM). Cell migration across the inflicted 
wounds were  photographed under the phase contrast microscope (Nikon) in 0 , 24 and 48 
h time intervals in three or more randomly selected fields. 
4.7.2.6 Hoechst staining 
A549/MDAMB-231 cells (25×104 cells/well) at their growth phase were seeded and 
allowed for 24 h to adhere. Test compound 45a in three different concentrations 0.5, 1 and 
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2 µM in culture medium was added to the cells and incubated for 48 h at 37 ᵒC.  Then, 
culture medium was removed from the wells, washed with PBS and stained with Hoechst 
33242 (5 µg/mL) for half an hour at room temperature. Excess dye was removed by PBS 
washing twice after which, morphological changes in the cells were examined with 
fluorescence microscope using 350 nm excitation and 460 nm emission (Nikon, 
magnification 10X).  
4.7.2.7 Measurement of Mitochondrial membrane Potential (MMP) 
In a 6 well plate A549/ MDAMB-231 cells were cultured at a density of 5×105cells/mL and 
incubated for overnight. Then the test compound at 0.5, 1 and 2 µM concentrations was 
added to the wells. 24 h after the treatment, adherent cells were collected by trypsinisation, 
washed with PBS (500 µL) and treated with the 400 µL/well of Rhodamine-123 solution in 
PBS (2 µM) in the absence of light. After 30 min of incubation at room temperature, cells 
were twice washed with PBS and resuspended in PBS.  The samples were then analysed for 
fluorescence using spectrofluorometer. 
4.7.2.8 Measurement of reactive Oxygen Species (ROS) levels 
A549 cells were seeded in a 6 well plate at a density of 5×105 cells/mL and allowed to grow 
overnight. The cells were incubated with the 0.5, 1 and 2 µM concentration of compound 
45a for 24 h. After which the medium was removed from the wells, culture medium 
containing DCFDA (10 µM) was added to the wells in the dark and incubated for half an 
hour at ambient temperature. Cells were washed with PBS, collected and resuspended in 
PBS. Intensity of the formed 2', 7'-dichlorofluorescein as a result of Carboxy-DCFDA 
hydrolysis, was analysed in spectrofluorometer at an excitation and emission wavelength 
of 488 and 525 nm respectively. Qualitative cellular fluorescence images were captured by 
Nikon ECLIPSETE2000-S fluorescence microscope.  
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Concluding statements 
In conclusion, two novel peptide based triazole organocatalysts 1 and 1a has been 
developed for the enantiomeric Michael addition reaction. The very low catalyst loading 
(0.5 mol %) has been achieved in the transformation which is a striking feature of the 
work. Employing low catalyst loading in reactions is an attractive strategy, where the 
catalyst  recovery is difficult or not possible. Simple reactions involved in the preparation 
of catalysts facilitate the easy access to these catalysts in gram scale. Detailed NMR and 
molecular modelling studies established possible reaction mechanism. The results of this 
work were published in a peer reviewed journal (RSC Advances 2014, 4, 30325-30331. DOI: 
10.1039/C4RA04165H). On the other hand, among the series of dibenzodiazepinone-triazole 
hybrid molecules tested for anti-cancer activity, 45a exhibited potent in vitro cytotoxic 
activity with IC50 values in the range of 0.71-7.29 µM compared with 5-Fluorouracil, a FDA 
approved anticancer drug. From the apoptotic studies it was evident that, 45a has the 
potential to be developed as lead and its further structural modification may produce 
promising anticancer agents. The results of this work have been published in a peer 
reviewed journal (Eur. J. Med. Chem. 2015 DOI:10.1016/j.ejmech.2015.12.007) 
Future work 
There are many elements of this investigation that could be subject of further exploration. 
One of the key interests is preparation of a library of peptides by coupling different amino 
acid residues to the triazole esters 2/2a and evaluation of the synthesised peptide library 
and peptides 1 and 1a in various asymmetric organic reactions like aldol, Mannich, 
epoxidation, hydrogen transfer, Diels-Alder etc., this may produce more efficient catalysts 
in terms of stereo-selectivity, reaction time, and yields than existing organocatalysts. On 
the other hand, conducting the reactions in water as solvent, recovery and reuse of peptide 
catalysts is another attractive topic of interest. Another topic of further research would be 
utilization of peptide catalysed reactions in the synthesis of various biologically or 
pharmacologically active natural products and other organic compounds. Evaluation of 
dibenzodiazipinone-triazole hybrids for anti-fungal, anti-bacterial and anti-tuberculosis 
activity is also one of our future interests.  
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IR spectrum of compound 1 
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HRMS spectrum of compound 4a 
HRMS spectrum of compound 5a 
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1
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IR spectrum of compound 1a 
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CHAPTER-III 
Cartesian Coordinates of Transition State Structures 
The B3LYP/6-31G (d) optimized geometries (Cartesian coordinates in (A0)), total electronic 
energies (in hartree/particle), of transition states of different stereochemical modes of addition of 1 
enamine to nitro styrene. The values in the parenthesis implies zero-point corrected energies 
evaluated at the PCM-B3LYP/6-31G (d) level of theory. 
1-anti enamine+ re nitrostyrene 
Et = -1845.1601392 (-1844.567544) 
C -0.658388 2.065377 0.899325 
C 0.431445 3.146661 0.920702 
C 1.608733 2.48284 0.196215 
N 0.985216 1.441204 -0.665242 
C -0.486796 1.410955 -0.481867 
C -1.205937 2.186357 -1.617355 
N -2.641222 2.343604 -1.371048 
N -3.146068 3.588549 -1.254060 
N -4.430867 3.485851 -1.016588 
C -4.759612 2.170504 -0.958889 
C -3.623320 1.414094 -1.185128 
C -3.380048 -0.053760 -1.233746 
O -2.510569 -0.544664 -1.964659 
N -4.149905 -0.775541 -0.394907 
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C -4.003205 -2.208006 -0.199170 
C -5.236773 -2.638541 0.632511 
N -5.408720 -3.965257 0.753115 
C -2.653064 -2.517193 0.499783 
C -2.134588 -3.936043 0.322595 
O -0.836420 -4.110259 0.536434 
O -2.838743 -4.892795 0.022734 
O -5.988491 -1.790610 1.121662 
H -1.663252 2.466154 1.051577 
H -0.473501 1.309467 1.669585 
H 0.102107 4.042058 0.383986 
H 0.704214 3.450992 1.933983 
H 2.290367 2.007480 0.903693 
H 2.185941 3.175968 -0.423482 
H -0.815136 0.372487 -0.489797 
H -1.076110 1.686075 -2.576525 
H -0.818159 3.202652 -1.701117 
H -5.774373 1.841689 -0.785453 
H -4.839485 -0.341261 0.213115 
H -6.136484 -4.303487 1.369099 
H -4.665919 -4.594942 0.450037 
H -1.896472 -1.837902 0.101846 
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H -2.715280 -2.307574 1.575166 
H -4.024181 -2.715787 -1.169128 
C 1.702894 0.613028 -1.441047 
C 3.105866 0.542476 -1.305457 
C 3.958053 -0.01776 -2.429642 
C 3.243721 -1.061696 -3.296604 
C 1.836988 -0.584291 -3.663958 
C 1.004035 -0.337261 -2.395823 
H 3.585320 1.344136 -0.754830 
H 4.268585 0.825449 -3.066184 
H 4.887295 -0.429102 -2.018166 
H 3.835249 -1.255489 -4.199009 
H 3.171165 -2.016595 -2.758068 
H 1.899114 0.339594 -4.254930 
H 1.322247 -1.326178 -4.284865 
H 0.007283 0.017837 -2.656595 
H 0.860258 -1.285217 -1.867220 
H -0.330356 -3.242688 0.619818 
C 5.127484 0.353361 1.520899 
C 6.476680 0.480678 1.840928 
C 7.409455 -0.437936 1.347064 
C 6.980578 -1.483789 0.528744 
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C 5.628671 -1.609964 0.204654 
C 4.679086 -0.697921 0.699335 
H 4.420255 1.082345 1.906685 
H 6.803001 1.300067 2.475177 
H 8.461327 -0.335408 1.598021 
H 7.695642 -2.204132 0.141618 
H 5.299764 -2.434985 -0.421490 
C 3.249684 -0.900664 0.368656 
H 3.044188 -1.736540 -0.291424 
C 2.280141 -0.688604 1.371942 
H 2.448879 -0.103438 2.264046 
N 1.052357 -1.276460 1.335208 
O 0.244778 -1.131613 2.290727 
O 0.724783 -2.002767 0.320349 
1-anti enamine+sinitro styrene 
Et = -1845.1580996 (-1844.565963) 
C -1.476346 -2.742149 -1.759722 
C -0.962423 -3.755722 -2.791742 
C -0.104213 -2.894315 -3.722326 
N 0.369416 -1.775552 -2.867776 
C -0.267564 -1.819176 -1.529250 
C 0.712817 -2.376492 -0.465711 
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N 0.058593 -2.557668 0.830662 
N -0.128381 -3.806448 1.301483 
N -0.783924 -3.720012 2.434040 
C -1.041112 -2.412619 2.689048 
C -0.510548 -1.643290 1.667831 
C -0.451824 -0.172679 1.449034 
O 0.493307 0.360294 0.854225 
N -1.504114 0.508142 1.945632 
C -1.586923 1.956939 1.954205 
C -2.702423 2.299899 2.972879 
N -2.797177 3.598849 3.297951 
C -1.862241 2.528768 0.537062 
C -1.381338 3.962304 0.359622 
O -1.255413 4.409418 -0.880035 
O -1.122216 4.705788 1.299660 
O -3.426517 1.411991 3.432539 
H -1.830072 -3.208818 -0.837614 
H -2.298729 -2.153041 -2.178876 
H -0.357301 -4.531242 -2.310622 
H -1.768517 -4.254300 -3.335192 
H -0.708007 -2.499998 -4.545474 
H 0.750646 -3.424807 -4.151977 
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H -0.571735 -0.807330 -1.257668 
H 1.567191 -1.714818 -0.330230 
H 1.075390 -3.365304 -0.750101 
H -1.557933 -2.095966 3.583819 
H -2.269682 0.043182 2.427097 
H -3.551518 3.899987 3.900444 
H -2.216663 4.283325 2.816590 
H -1.367067 1.897718 -0.206445 
H -2.933855 2.492875 0.301828 
H -0.636876 2.369443 2.309816 
C 1.071627 -0.737854 -3.356371 
C 1.303346 -0.593663 -4.742804 
C 2.504913 0.190101 -5.241753 
C 2.975373 1.302456 -4.296061 
C 2.994022 0.812862 -2.846683 
C 1.588994 0.340562 -2.432226 
H 1.060784 -1.447295 -5.366765 
H 3.326164 -0.529383 -5.385749 
H 2.294915 0.594207 -6.239386 
H 3.969860 1.647458 -4.602453 
H 2.302959 2.166519 -4.371294 
H 3.713063 -0.009351 -2.731783 
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H 3.312180 1.613258 -2.169082 
H 1.572689 0.029012 -1.388602 
H 0.907873 1.196738 -2.502490 
C 0.177840 1.305350 -7.598815 
C 0.240925 1.120557 -8.979941 
C -0.283586 -0.035661 -9.562311 
C -0.873141 -1.009688 -8.751606 
C -0.931031 -0.827964 -7.371613 
C -0.411148 0.332604 -6.769319 
H 0.586915 2.214916 -7.170420 
H 0.699304 1.884375 -9.601679 
H -0.234755 -0.176181 -10.638311 
H -1.289450 -1.910271 -9.194004 
H -1.395978 -1.589861 -6.750446 
C -0.529552 0.492723 -5.301373 
H -1.149708 -0.248576 -4.808741 
C -0.631514 1.783566 -4.745377 
H -0.331512 2.691455 -5.245025 
N -1.212741 1.998052 -3.529985 
O -1.391941 3.218742 -3.175574 
O -1.582062 1.047773 -2.783279 
H -1.407283 3.731822 -1.609703 
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The B3LYP/6-31G (d) optimized geometries (Cartesian coordinates in (A0)), total electronic 
energies (in hartree/particle), of transition states of different stereo chemical modes of addition of 
1a enamine to nitro styrene. The values in the parenthesis implies zero-point corrected energies 
evaluated at the PCM-B3LYP/6-31G (d) level of theory. 
1a-anti enamine+ re nitro styrene 
Et = -1845.1434395 (-1844.551983) 
C 3.035325 -5.412734 -2.973328 
C 3.132865 -5.403444 -1.439778 
C 1.744605 -4.924013 -0.985617 
C 1.365582 -3.880307 -2.047152 
N 1.927342 -4.465005 -3.284348 
C 1.987470 -2.488452 -1.763073 
N 1.261865 -1.789778 -0.704584 
C 1.629250 -1.532348 0.568114 
C 0.547720 -0.859033 1.112778 
N -0.412444 -0.749230 0.144327 
N 0.017531 -1.308103 -0.948912 
C 0.313114 -0.292852 2.467135 
O -0.774595 0.178990 2.789515 
N 1.392410 -0.318001 3.314307 
C 1.300182 0.094118 4.706582 
C 2.066534 1.396565 5.034273 
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N 2.492653 2.118064 3.977387 
H 2.252838 -0.754788 3.008799 
H 2.959686 3.000047 4.138267 
H 2.334307 1.816184 3.027478 
O 2.232470 1.736185 6.205226 
C 1.752421 -1.020084 5.667296 
C 0.883241 -2.257404 5.627258 
O -0.428089 -1.962665 5.758982 
O 1.293794 -3.394357 5.515796 
H 2.785911 -6.404748 -3.349133 
H 3.953707 -5.076758 -3.465690 
H 3.915495 -4.713162 -1.108397 
H 3.382458 -6.392630 -1.048634 
H 1.019527 -5.743151 -1.022667 
H 1.740716 -4.508850 0.026266 
H 0.283216 -3.786829 -2.158013 
H 3.02767 -2.577636 -1.444938 
H 1.965025 -1.852682 -2.649257 
H 2.588737 -1.837030 0.957823 
H 0.243329 0.315338 4.880751 
H 1.729753 -0.607555 6.681288 
H 2.779695 -1.329133 5.455739 
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H -0.919901 -2.806281 5.734610 
C 1.485225 -4.214038 -4.524510 
C 1.893419 -5.021242 -5.615604 
C 1.852645 -4.440319 -7.023048 
C 0.710896 -3.443812 -7.252421 
C 0.649476 -2.425139 -6.112285 
C 0.446749 -3.133520 -4.762742 
H 2.759767 -5.651915 -5.442358 
H 2.811787 -3.931199 -7.203682 
H 1.805752 -5.252421 -7.756255 
H 0.852821 -2.937699 -8.214522 
H -0.24919 -3.974232 -7.315716 
H 1.577587 -1.838035 -6.087126 
H -0.171861 -1.715719 -6.264601 
H 0.434283 -2.402493 -3.953346 
H -0.534088 -3.622997 -4.748296 
C 2.080464 -8.301695 -6.432576 
C 2.499023 -9.146805 -7.458514 
C 1.819054 -9.162960 -8.680599 
C 0.719685 -8.323551 -8.867879 
C 0.302804 -7.474491 -7.840775 
C 0.970719 -7.455448 -6.604843 
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H 2.625133 -8.294343 -5.492313 
H 3.359528 -9.792308 -7.305560 
H 2.147234 -9.821698 -9.479677 
H 0.184228 -8.326736 -9.813286 
H -0.558118 -6.828474 -7.992604 
C 0.469354 -6.573611 -5.515032 
H -0.363112 -5.935497 -5.797350 
C 0.357458 -7.139765 -4.224349 
H 0.884242 -8.029553 -3.911692 
N -0.459753 -6.614617 -3.261088 
O -0.554454 -7.214940 -2.146711 
O -1.126325 -5.555705 -3.482409 
1a-anti enamine+ siβ-nitrostyrene 
Et = -1845.1395547 (-1844.548347) 
C 3.439905 -4.545805 -3.121808 
C 3.621987 -4.359378 -1.611820 
C 2.214998 -3.965248 -1.138102 
C 1.703080 -3.051430 -2.262346 
N 2.320585 -3.636556 -3.473366 
C 2.149839 -1.578100 -2.085084 
N 1.327497 -0.888483 -1.093456 
C 1.636401 -0.490972 0.158759 
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C 0.475369 0.098386 0.631750 
N -0.468269 0.028199 -0.356183 
N 0.043517 -0.570452 -1.392185 
C 0.167118 0.761302 1.926407 
O -0.804155 1.501165 2.059624 
N 1.056049 0.504461 2.941915 
C 0.863608 1.018896 4.290150 
C 1.919726 2.060444 4.727274 
N 2.723018 2.537230 3.754862 
H 1.737229 -0.234019 2.815833 
H 3.402560 3.250554 3.981150 
H 2.652434 2.213357 2.801630 
O 1.971565 2.428953 5.900133 
C 0.800102 -0.110963 5.334091 
C -0.375854 -1.044558 5.151297 
O -1.548354 -0.376974 5.095971 
O -0.302823 -2.254176 5.080120 
H 3.161777 -5.578556 -3.354082 
H 4.329545 -4.290448 -3.704837 
H 4.343388 -3.561173 -1.406671 
H 3.991145 -5.269983 -1.134299 
H 1.570627 -4.848062 -1.076423 
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H 2.206439 -3.471875 -0.162243 
H 0.616250 -3.100037 -2.356546 
H 3.187872 -1.518109 -1.753159 
H 2.065614 -1.025151 -3.021833 
H 2.621599 -0.628225 0.577615 
H -0.093265 1.548456 4.272584 
H 0.729283 0.357887 6.320716 
H 1.711595 -0.714640 5.314026 
H -2.256472 -1.040254 4.982798 
C 1.792637 -3.562302 -4.703505 
C 2.226875 -4.408606 -5.759651 
C 2.151406 -3.886530 -7.191430 
C 0.966133 -2.952409 -7.465171 
C 0.821730 -1.914671 -6.350735 
C 0.650547 -2.621342 -4.993016 
H 3.144154 -4.959062 -5.569436 
H 3.087317 -3.342614 -7.391612 
H 2.143843 -4.729461 -7.891057 
H 1.103314 -2.460864 -8.435595 
H 0.037884 -3.533931 -7.532202 
H 1.703557 -1.260806 -6.321176 
H -0.048149 -1.271744 -6.526259 
Appendix 
 
135 | P a g e  
 
H 0.494775 -1.894349 -4.196022 
H -0.261500 -3.233239 -5.045286 
C 1.019418 -7.080583 -7.872602 
C 1.583116 -7.962905 -8.794814 
C 2.689255 -8.740349 -8.443067 
C 3.229580 -8.627067 -7.159588 
C 2.667334 -7.742518 -6.240111 
C 1.550286 -6.957714 -6.575993 
H 0.157687 -6.489341 -8.166830 
H 1.154589 -8.043459 -9.790007 
H 3.125288 -9.428262 -9.161991 
H 4.087124 -9.229361 -6.872517 
H 3.092207 -7.665010 -5.241941 
C 0.966225 -6.057910 -5.543016 
H 1.328681 -6.256821 -4.539550 
C -0.422573 -5.783615 -5.571501 
H -1.054736 -5.871978 -6.441787 
N -1.096924 -5.442295 -4.426931 
O -2.356086 -5.320563 -4.467516 
O -0.460242 -5.255218 -3.340881 
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NMR-Experiments 
TOCSY, HSQC and proton Spectra of 1a in 500 l of 90% D2O and 10% H2O (700MHz, 298K) 
 
                         TOCSY                                                                                                 HSQC 
 
 
1H NMR Spectrum of 1a 500 l of 90% D2O and 10% H2O (700MHz, 298K)
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1H NMR Spectrum of 1 in 500 l of 90% D2O and 10% H2O (700 MHz, 298K) 
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NMR and Mass spectra of selected compounds 
 
  
1
H-NMR (500 MHz, CDCl3) of compound 4b 
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C-NMR (125 MHz, CDCl3) of compound 4b 
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IR spectrum of compound of compound 4b 
HRMS spectrum of compound 4b 
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1H NMR of compound 10c (CDCl3, 500 MHz) 
13CNMR of compound 10c (CDCl3, 125 MHz) 
  
HRMS spectrum of compound 4c 
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H-NMR of compound 4g (300 MHz, CDCl
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1
H-NMRof compound 4h (300 MHz, CDCl
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)  
 
1
H NMR of compound 4i (300 MHz, CDCl3)  
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1
H-NMRof compound 4j (500 MHz, CDCl3)  
13
C-NMRof compound 4j (125 MHz, CDCl3)  
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HRMS spectrum of compound 4j 
IR spectrum of compound 4j 
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1
H NMR of compound 4k (300 MHz, CDCl3)  
13
C NMR of compound 4k (75 MHz, CDCl3)  
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1
H-NMR of compound 4l (300 MHz, CDCl3) 
13
C-NMR of compound 4l (75 MHz, CDCl3)  
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IR spectrum of compound 4l 
IR spectrum of compound 4l 
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 X-ray Crystallographic data of compound 39 
Identification code praveen_00103 
Moiety compositionC28 H24 N4 O2 
Empirical formula C28 H24 N4 O2 
Formula weight448.51 
Temperature150(2) K 
Wavelength0.71073 Å 
Crystal system Triclinic 
Space groupP-1 
Unit cell dimensionsa = 10.9202(12) Å α= 97.141(4)°. 
b = 12.4179(17) Å β= 107.697(4)°. 
c = 13.0883(17) Åγ = 93.392(5)°. 
Volume 1668.9(4) Å3 
Z 3 
Density (calculated) 1.339 Mg/m3 
Absorption coefficient 0.086 mm-1 
F(000) 708 
Crystal size 0.450 x 0.350 x 0.300 mm3 
Theta range for data collection 1.652 to 26.000°. 
Index ranges -12<=h<=13, -15<=k<=15, -16<=l<=15 
Reflections collected 20184 
Independent reflections 6515 [R(int) = 0.0322] 
Observed reflections [I>2sigma(I)] 4355 
Completeness to theta = 26.000° 99.3 % 
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters6515 / 77 / 588 
Goodness-of-fit on F21.115 
Final R indices [I>2sigma(I)]R1 = 0.0566, wR2 = 0.1596 
R indices (all data) R1 = 0.0923, wR2 = 0.1789 
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Extinction coefficientn/a 
Largest diff. peak and hole 0.210 and -0.227 e.Å-3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
